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Abstract 
The role of Syk kinase in UV mediated skin damage 
Huang, Zhenyu 
Advisor: Dr. Elisabeth S Papazoglou 
 
Ultraviolet (UV) irradiation is the main cause of skin photo-damage with resulting 
modulation of matrix metalloproteinases (MMPs) leading to collagen degradation. There 
is no easily accessible molecular indicator of early skin UV damage. In this study, we 
investigated the effects of Spleen tyrosine kinase (Syk) on MMP expression and 
evaluated the sensitivity and usefulness of Syk as an early indicator of skin UV damage. 
Human Dermal Fibroblasts (HDFs) were transfected with Syk cDNA to 
overexpress Syk. MMP-1 expression and Syk activity were determined by western blot 
after UV exposure. The effect of Syk on MMP-1 expression in HDFs or human dermal 
keratinocytes (HDKs) was further explored by either Syk siRNA or a selective Syk 
inhibitor. Possible downstream molecules of Syk were also evaluated in HDFs upon UV 
exposure. The relationship between Syk and collagenase was further explored in vivo 
(MMP-13, hairless mice). 
Our studies in HDFs and HDKs demonstrated that both a Syk inhibitor and Syk 
siRNA were able to inhibit MMP-1 expression in these cells in response to UV exposure 
and that overexpression of Syk increased MMP-1 expression and the activity of JNK 
xiii 
 
kinase, but not p38 or Erk1/2 MAP kinase. UV exposure enhanced both expression and 
activity of Syk in HDFs and HDKs. Experiments with hairless mice suggest that Syk 
expression is an earlier indicator of UV exposure than MMP-13 expression. Furthermore, 
the results of Syk inhibitor (piceatannol) in hairless mice indicated that MMP-13 
expression was reduced in the presence of piceatannol. It suggests that not only Syk 
expression but its activity is important for the effect on UV induced skin damage. Finally, 
our data from human biopsies demonstrate that elevated Syk expression can be found in 
UV exposed skin compared to skin unexposed to UV. Although the evaluated sample 
number is not large, the difference is statistically significant. 
Our results demonstrate that Syk expression correlates well with increase of 
MMPs (MMP-1 in humans and MMP-13 in mice) in response to UV exposure. The 
findings suggest that Syk may be a novel target for the prevention and treatment of skin 
photodamage by modulating MMPs. 
xiv 
 
Executive Summary 
 
Ultraviolet (UV) irradiation is the main cause of skin photo-damage with resulting 
modulation of matrix metalloproteinases (MMPs) leading to collagen degradation. Many 
known changes in matrix metalloproteinases occur only after very prolonged UV 
exposure and damage and as such are not useful early indicators that could be used as 
warning signs. In this study, we investigated the effects of Spleen tyrosine kinase (Syk) 
on MMP expression and evaluated the sensitivity and usefulness of Syk as an early 
indicator of skin UV damage. 
First, we determined Syk kinase expression and activity in response to UV 
exposure, in vitro and in vivo. Syk expression in response to UV exposure was 
investigated in Human dermal fibroblasts (HDFs) and keratinocytes (HDKs), using 
reverse transcription-polymerase chain reaction (RT-PCR), because the level of Syk 
expression in normal HDFs or HDKs is very low. The RT-PCR results demonstrate that 
UVB enhances Syk expression in HDFs and HDKs. The results also indicate higher Syk 
tyrosine phosphorylation in cells exposed to UV vs. unexposed cells, suggesting 
enhanced Syk activation upon UV exposure. Syk tyrosine phosphorylation exhibited a 
maximum 25 min after UV exposure and its activation lasted for at least 45 min. Our in 
vivo experiments in hairless mice (SKH1) confirmed that Syk expression was 
dramatically enhanced in skin samples after either 5 or 10 weeks of UV exposure. After 
we obtained the results in cells and animal model (SKH1), Syk expression was further 
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compared between normal and UV damaged biopsy samples of human skin (paraffin 
blocks) by immunohistochemistry. The result indicated that there was a significant 
difference between normal vs. UV exposed samples on Syk expression despite the small 
number of samples evaluated. These results indicate that UV exposure enhances Syk 
expression not only in cell lines, in mouse skin but also in human skin as a response to 
UV exposure. 
We evaluated next the effect of Syk kinase on known markers of UV damage, in 
vitro and in vivo. It has been well established that MMP-1 (in humans) and MMP-13 (in 
mice) overexpression are the hallmarks of UV induced damage. HDFs were transfected 
with Syk cDNA to over-express Syk. MMP-1 expression was determined by western blot 
after UV exposure. More MMP-1 can be detected in HDFs that overxpress Syk. In order 
to confirm the correlation between Syk and MMP, inhibitor-Syk siRNA was used to 
inhibit / knock down Syk expression in HDFs over-expressing Syk. And as a result, 
MMP-1 expression was dramatically reduced in those HDFs. In order to further confirm 
our findings in vivo, hairless mice were exposed to UVR for either 5 or 10 weeks. Syk 
and MMP-13 expression were measured in skin harvested from the mice after UV 
exposure. Our results show that Syk expression was dramatically enhanced in skin 
samples after either 5 or 10 weeks of UV exposure. However, MMP-13 expression was 
found to clearly increase only in the samples exposed to UV for 10 weeks, and showed 
no significant increase in skin samples exposed to UV for 5 weeks. These results 
demonstrate that Syk is altered earlier than MMP-13 in the skin of hairless mice after UV 
exposure, and suggest that Syk might be an earlier biomarker for UV induced photo-
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damage. Therefore, Syk enhances expression of collagenase: MMP-1 in HDFs in vitro 
and MMP-13 in the skin of hairless mice in vivo. In the studies on the effects of possible 
molecules downstream of Syk, our results demonstrate that Syk only enhances JNK 
activity, but not p38 or Erk1/2 activities. Moreover, based on the result of reblotting with 
anti-JNK, the enhanced phospho-JNK was phospho-JNK1. These data suggest that Syk 
might affect MMP-1 expression by modulating JNK1 activity, and thus play an important 
role in UV induced skin photo-damage. 
Finally, we evaluated the effect of a Syk kinase inhibitor (piceatannol) on known 
UV damage markers: MMP-1 in human and MMP-13 in mouse. In order to further 
confirm the above findings and explore the potentials for therapeutic application, the 
effect of Syk inhibitor (piceatannol) on UV induced skin damages has been studied in 
vitro and in vivo. The dose-response of piceatannol inhibition was assessed in HDFs and 
HDKs exposed to UVB. Our western blot data indicated that MMP-1 expression was 
dramatically inhibited by piceatannol at a concentration of 25 g/ml, while there was no 
inhibition of MMP-1 expression at lower concentrations of piceatannol such as 1 g/ml. 
In order to further confirm this finding in vivo, the skin of SKH1 mice was pretreated 
with Syk inhibitor (piceatannol) before every scheduled UV exposure. After 10 weeks of 
UV exposure, the mice were sacrificed and their skin collected for MMP-13 expression 
assay by western blot. The results indicate that MMP-13 expression was inhibited in the 
piceatannol treated groups vs. the no piceatannol treated group. This suggests that not 
only Syk expression but its activity is important for the effect of Syk on UV induced skin 
damage.   
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In conclusion, our results in vitro and in vivo demonstrate that Syk expression 
correlates well with increase of MMPs (MMP-1 in humans and MMP-13 in mice) in 
response to UV exposure.  And both Syk expression and its activity are required for Syk 
playing an important role in UV induced skin damages. Syk may affect MMP-1 
expression by modulating JNK activity. These new findings suggest that Syk may 
become a useful therapeutic target and an earlier biomarker compared with MMP-1 for 
UV induced skin photo-damage. 
  In our future plans, we would like to link Syk overexpression in response to UV 
to carciongenesis. We plan to do this by etsablishing a skin carcinoma animal model 
based on SKH1 hairless mice exposed to UV. The role of Syk inhibitors (piceatannol or 
R788) in preventing skin carcinogensis will be determined in this animal model. 
Compared with chemical inhibitors, Syk siRNA is thought as a more specific and less 
side effect prone inhibitor for Syk kinase. Therefore, Syk siRNA also will be evaluated as 
a potential for preventing UV damage and progression to skin carcinogenesis in this 
animal model. At the same time continuing to  test samples obtained from biopsies of 
various skin cancers to establish if Syk is differentially expressed in basal or squamous 
cell carcinomas is very valuable and we will try to obtain a sample population that will 
allow statistically reliable analysis.  
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The role of Syk kinase in UV mediated skin damage 
Chapter 1: Introduction 
 
1. Ultraviolet (UV) radiation and skin damage  
1.1 UV  
Sunlight is composed of a continuous spectrum including UV light (5% content in 
sunlight), visible light (50%), and infrared (45%) [1]. Ultraviolet radiation (UVR) from 
sunlight is a major etiologic factor in human skin photoaging and photocarcinogenesis. 
The ozone layer blocks wavelengths below 290nm. Therefore, it blocks all of UVC (180-
280nm) and most part of UVB. Of the UV light which reaches the surface of the Earth, 
5% or less is UVB while the remaining 95% is UVA [2]. It is generally thought that UVB 
(280-320nm) and UVA (320-400nm) are responsible for sunlight-induced skin 
photodiseases [3, 4].  
 
1.2 Human skin   
Human skin is composed of an outer epidermis supported by an underlying 
dermis and hypodermis (Fig.1.1). The epidermis has five layers: stratum basale, stratum 
spinosum, stratum granulosum, stratum lucidum and stratum corneum. The stratum 
basale is the inner most layer of the epidermis and contains rapidly proliferating and 
differentiating keratinocytes, Merkel cells and melanocytes. The stratum spinosum layer 
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contains Langerhans cells, which are part of skin immune system [5, 6]. The dermis 
consists mostly of secreted proteins to provide structural support for the skin, which are 
known as the extracellular matrix. Collagen type I (70% of skin collagen) constitutes the 
major structural component of dermal connective tissue, which comprises 90% of the dry 
weight of the skin and diminishes with normal aging [7, 8].  
 
 
Figure 1.1. Anatomy model of human skin. 
http://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/articles/image_
article_collections/anatomy_pages/skin.jpg 
 
1.3 Skin aging and UV induced skin damage  
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Human skin is the only organ directly exposed to UV radiation from the sun. 
Aging is a multistep process resulting in a decline in biological functions and the ability 
to adapt to metabolic stress. Both skin and the immune system are subject to 
chronological aging.  
Skin aging is the result of overlapping intrinsic chronological aging (individual, 
genetic) and extrinsic aging (photo-aging mainly dependent on UV exposure). Intrinsic 
skin aging is related to natural biological aging processes in sun-protected skin. In 
contrast to photo-aged skin, intrinsically aged skin appears smooth, pale, and finely 
wrinkled [9]. Degradation of a number of extracellular matrix proteins, including 
collagen and elastic fibers is the greatest difference between intrinsically aged and photo-
aged skin [9].  
In sun-exposed sites, the skin is subject to photo-aging. Soon after UV exposure,  
an early inflammatory event such as erythema and redness occurs due to vasodilation of 
cutaneous blood vessels [5]. This is often followed by the development of sunburn cells 
[5, 10]. Sunburn cells are keratinocytes which die by apoptosis as a result of UV 
exposure [5, 11]. Chronic exposure to UV results in skin photoaging, which is 
characterized by irregular pigmentation, dryness of the skin, wrinkling and elastosis [10, 
12, 13]. UVA (340–400 nm, 600 kJ/m2) can cause a decrease of Langerhans cells which 
are known to play an important role in presenting antigens in human skin [14]. Clinically, 
these changes in the skin manifest as mottled dyspigmentation, sagging of the skin, 
fragility, loss of elasticity, wrinkling, easy bruisability, accumulation of precancerous 
lesions, and epithelial and melanocytic neoplasms [15-17]. The immune system in normal 
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skin protects the skin from infection, provides surveillance for emerging cancers, 
removes damaged cells, and prevents undesirable autoimmune reactions against self 
proteins. However, upon sun exposure of the skin, the immune system may also promote 
the aging process. UV-induced inflammatory reactions may participate in the promotion 
of skin aging through generation of reactive oxygen species (ROS), proteolytic enzyme 
production, suppressed immune surveillance, and production of growth factors for 
incipient cancer cells. As we indicated, epidermal changes of chronological aging include 
thinning of the stratum spinosum and flattening of the dermo-epidermal junction [18]. In 
contrast to sun-protected epidermis, epidermal thickness is increased in sun-exposed skin 
[19]. Although the mechanism of thickness increase is unknown, senescent keratinocytes 
and melanocytes may become resistant to apoptosis and survive for a long time giving 
time for DNA damage to accumulate, with UV inflammation-associated growth factors 
contributing to tumor promotion [20]. Melanocyte growth (development of nevi, solar 
lentigo, and lentigo maligna) or their decrease (idiopathic guttate and hypomelanosis) in 
photoexposed areas may be due to direct apoptosis or immunological activity. The 
number of dendritic Langerhan cells (LCs) also decreases with age, and the cells have 
fewer dendrites and reduced antigen-trapping capacity [18, 21]. Both acute and chronic 
UV exposures further deplete this population [22-24].  
The numbers of fibroblasts is found to decrease in the dermis of chronologically 
aged skin, which will cause diminished capacity to produce type I procollagen compared 
to cells in young skin [25]. With chronological aging, cross-linking of collagen has been 
found to increase as a result of an enzyme-controlled process and a non-enzymatic 
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glycation process [26], which is associated with elevated levels of partially degraded 
collagen. Increased collagen fragments are also a prominent feature in photodamaged 
skin. Procollagen gene and protein expression are significantly reduced in the upper one-
third of the dermis of sun exposed skin likely reflecting the depth of penetration of UV 
irradiation [27]. Following chronic UV exposure, the composition of collagen is found to 
be comprised mostly by elevated levels of type III collagen [28]. Based on histological 
and ultrastructural studies, there is minimal change in the epidermis, while major 
alterations are seen in dermal connective tissue which is characterized by damaged and 
disorganized collagen fibrils, referred to as „„solar elastosis‟‟ [15]. These alterations 
include fragmentation of the dermal collagen matrix, reduced synthesis of types I and III 
collagen precursors and cross-links, and increased levels of elastin. It suggests that matrix 
degrading proteases participate in this process. Type I collagen is the major structural 
protein in the dermal ECM [30, 31]. Collagen precursor molecules (procollagen) are 
synthesized by dermal fibroblasts. Procollagen is secreted into extracellular spaces, where 
it is enzymatically processed to mature collagen. Mature collagen spontaneously forms 
fibrils, which are stabilized by cross-links. Collagen fibrils are largely responsible for the 
strength and resilience of skin. Since collagen fibrils can last a long time [31], fragmented 
collagen fibrils accumulate with the passage of time and have long lasting effects on skin 
structure and function. UV induced collagen fragmentation in dermis results from two 
primary pathways: (1) stimulation of collagen breakdown, resulting in fragmented, 
disorganized collagen and (2) inhibition of procollagen I and III biosynthesis, resulting in 
a loss of collagen content. A single exposure to UV radiation of 2 minimal erythemal 
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doses (MEDs) causes near-complete loss of procollagen synthesis, which can persist for 
24 hours, followed by recovery 48–72 hours later [32]. This reduction in procollagen 
synthesis is most likely mediated by impairment of transforming growth factor-β 
pathways, which control procollagen expression [33,34]. Matrix metalloproteinases 
(MMPs) are key mediators of the collagen degradation that is observed in photoaged skin 
(29,35,36). Although chronologically aging is thought as a different process from 
photoaging, they both share important common molecular features including collagen 
deficit, elevated MMP activities and connective tissue damage. This suggests that similar 
remediations maybe applied for both photoaged and naturally aged skin [25,37]. 
 
2. Matrix Metalloproteinases (MMPs) and skin damage  
The majority of skin disorders with aging and cancer are due to UV exposure. 
Matrix metalloproteinases (MMPs) are thought to play a major role in the pathology of 
photoaging. MMPs can be induced by both UVA and UVB radiation. [35,38,39] 
However, several differences have been found between UVA and UVB induced 
signaling. 
The shorter wavelength UVB is mostly absorbed in the epidermis (keratinocytes). 
Following UVB exposure, transcription factors AP-1 and NF-kB are induced, which can 
further activate the gene expression of MMPs. Compared to UVB, the longer wavelength 
UVA penetrates deeper and can affect both epidermal keratinocytes and dermal 
fibroblasts. UVA can mostly act on the expression of MMPs and mtDNA through the 
generation of reactive oxygen species (ROS) [40].  
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ROS can be divided into two categories: oxygen molecules that are in an excited 
state such as singlet oxygen (
1
O2) and oxygen molecules that have an unpaired electron 
including superoxide anion radicals (˙O2
-
), lipid peroxyl radicals (LOO˙), hydroxyl 
radicals (˙OH), and nitric oxide radicals (NO˙). Generation of different type(s) of ROS 
depends on the UV wavelength. UVB mainly produces ˙O2
-
 through the activation of 
NADPH oxidase and respiratory chain reactions [41,42], while UVA produces 
1
O2 
through a photosensitizing reaction with internal chromophores such as riboflavin and 
porphyrin. UVA has also been found to generate ˙O2
-
 through NADPH oxidase activation 
[43]. The major type of ROS produced on the skin surface is 
1
O2, which is generated by a 
photosensitizing reaction with UVA [44]. 
1
O2 is oxidized to squalene, cholesterol, and to 
unsaturated acyl residues in the sebum to yield lipid hydroperoxides. Oxidized lipids, 
such as linoleic acid hydroperoxide, enhance the expression of MMP-1 and MMP-3. The 
1
O2 generated by UVA irradiation has also been found to modulate MMP-1 expression in 
dermal fibroblasts through the secretion of interleukin (IL)-1α and IL-6 [45-47]. ROS can 
also activate c-Jun N-terminal kinase, which can further stimulate MMP-1 expression. 
The activation of JNK is due to the continuous phosphorylation of the epidermal growth 
factor receptor by ROS-dependent inactivation of protein tyrosine phosphatase [48]. An 
in vivo study showed that H2O2 accumulation in the skin due to a decrease in catalase 
also stimulates MMP-1 expression [49]. UV exposure attenuates the synthesis of new 
collagen, which is regulated by activator protein AP-1 [50], due to a reduction of collagen 
synthesis modulated by ROS and effects on MMP-1 expression. In fact, exposure of 
human dermal fibroblasts to ROS also decreases collagen synthesis [51]. 
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MMPs are a rapidly growing multigene family of zinc-dependent endopeptidases 
that are involved in the degradation of extracellular matrix (ECM) components in both 
physiologic and pathologic processes. Matrix metalloproteinases (MMPs) are thought to 
play an important role in the pathology of photoaging. At present, at least 19 different 
human MMPs have been cloned [52]. MMP expression and activation are regulated at 
several steps including transcriptional and post-transcriptional. Most MMPs are secreted 
as proMMPs which can be activated by the other proteases. As with all secreted 
proteinases, the catalytic activity of MMPs is regulated at four points: gene transcription 
and translation, compartmentalization such as secretory vesicles and pericellular 
accumulation, zymogen activation, and enzyme inactivation [53]. For the most part, the 
production of MMPs is regulated at the level of transcription. Regulation of expression of 
MMPs isoenzymes is a very complex process performed by a number of different ways, 
e.g., histone modifications, transcription factors induced or inhibited by some signaling 
pathways, regulation of mRNA stability and protein translation. Some isoenzymes are 
coregulated, whereas others are not. The related factors include cytokines (e.g., TNFα, 
IL-1 and -6) and growth factors (e.g., epidermal growth factor and basic fibroblast growth 
factor), and external agents like UV irradiation. Interferon-γ, heparin, and vitamin A have 
been reported to inhibit MMP expression by inhibition of its gene transcription [52-54]. 
Physiologically, the activity of MMPs is inhibited by two major types of 
endogenous inhibitors, but several minor ones have also been reported [55]. The first 
major one is a nonspecific inhibitor, α2-macroglobulin, a 725 kDa plasma glycoprotein 
which can entrap most proteinases. The second major one is the group of the specific 
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endogenous tissue inhibitors of metalloproteinases (TIMPs), which comprise a family of 
four protease inhibitors: TIMP-1, TIMP-2, TIMP-3, and TIMP-4. These small (∼23 
kDa), two-domain proteins are 40–50% identical in sequence [56]. TIMPs inhibit MMP 
activity by binding noncovalently in a 1:1 stoichiometric ratio with relatively low 
selectivity [57]. They are found both in the intra- and extracellular space. One of the 
minor endogenous inhibitors for MMPs is fucose (6-deoxy-L-galactose), a fundamental 
carbohydrate subunit of the mammalian cell surface glycoproteins, which might act via a 
receptor-mediated pathway [58, 59]. 
MMPs can be classified in several classes. (Collagenases: MMP-1, MMP-8, 
MMP-13, MMP-18; Gelatinases: MMP-2, MMP-9; Stromelysins: MMP-3, MMP-10;  
Metalloelastase: MMP-12;  Matrilysin: MMP-7;  Membrane type: MT1-MMP, MT2-
MMP, MT3-MMP, MT4-MMP, MT5-MMP, MT6-MMP;  Others: MMP-11, MMP-19, 
MMP-20). [52,60-63] Collagenases are capable of hydrolyzing fibrillar collagen and 
cleaving it in triple helical domain, then collagen can be further broken down by 
gelatinases and stromelysins. Collagenase 1 (MMP-1), gelatinase A (MMP-2), gelatinase 
B (MMP-9) and stromelysin 1 (MMP-3) can fully degrade both skin collagen (collagen 
type 1) as well as components of the elastic network. [52-54] 
The published results have demonstrated that among the 19 MMPs expressed in 
normal human skin, UV radiation elevates at least three different MMPs in human skin in 
vivo: interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), and the 92-kDa 
gelatinase (MMP-9) [36,64,65]. These three MMPs are strongly regulated by the 
transcription factor activator protein-1 (AP-1), which is rapidly induced and activated by 
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UV radiation in human skin in vivo [36,52,66]. As indicated, the combined actions of 
MMP-1, -3, and -9 have the capacity to degrade most of the proteins that comprise the 
dermal ECM. MMP-1 is the only enzyme that is able to initiate cleavage of the collagen 
triple helix, which consists of the two major fibril-forming molecules in the skin, type I 
and III collagens. MMP-3 and -9 can cleave dermal fibrillar collagens (type I, III, and V) 
only after initiation of cleavage by MMP-1 [67]. This is why the activity of MMP-1 
remains under tight control even after UV irradiation. Despite elevated MMP-1 levels, 
only a small proportion of MMP-1 becomes active, whereas the majority of MMP-1 
remains in its inactive pro-form even after acute UV irradiation [68]. It has been also 
shown that MMP-1 might be the mediator of extrinsic skin-aging effects of tobacco 
smoking in vivo [69]. In smokers, facial aging might occur as the combined MMP-1 
inducing effect of sunlight and smoking. 
 
3. Protection of UV induced skin damage 
There are many ways to achieve protection of skin from photoaging. Clothing and 
glasses are still the most basic photoprotective tools. The photoprotective capability of 
clothing depends on its thickness and color. Usually dark colors protect more efficiently 
[70]. Both organic and inorganic UV “absorbers” are also being used to block the 
detrimental effects of sunlight. Sunscreen products are primarily designed to protect the 
skin from the harmful effects of solar UV radiation, and contain molecules or molecular 
complexes that can absorb, reflect, or scatter UV photons. In systemic photoprotection, a 
new strategy is to develop antioxidants to protect from photoaging through their effects 
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against reactive oxygen species (ROS), which is thought as one of major factors in 
photoaging. [71-73]. Eller & Gilchrest among other groups showed that oligo-nucleotides 
containing thymine dinucleotides (pTpT) not only induced tanning of the skin but also 
provided protective effects against photoaging and photocarcinogenesis [74,75].  It was 
also found that Lycopene (the major carotenoid of tomatoes) is an efficient singlet 
oxygen quencher [76]. Seresis is another antioxidant combination which contains 
physiological levels of lipid- and water-soluble compounds, including carotenoids (beta-
carotene and lycopene), vitamins C and E, selenium, and proanthocyanidins [77]. A 
clinical, randomized, double-blind, parallel-group, placebo-controlled study showed that 
Seresis could slow down the development of UVB-induced erythema and decrease UV-
induced expression of  both MMP-1 and MMP-9 [78]. 
Several studies have demonstrated that Vitamin A (Retinoic acid, molecular 
weight: 300, molecular formula: C20H28O2) can stimulate new collagen deposition both in 
sun-protected aged skin as well as in photoaged skin. Vitamin A also reduces MMP 
expression and enhances collagen synthesis in both naturally aged and photoaged skin.  
Vitamin A metabolites such as all-trans retinoic acid  
(tretinoin) have all been found to play an important role  
in preventing the loss of collagen and stimulating new collagen formation [25,35,79-82]. 
Green tea polyphenols such as Epigallocatechin-3-gallate also have been found to prevent 
UVB-induced skin tumors and inhibit MMP expression in mice [83]. In organic or 
chemical filter studies, Cinnamates are most frequently used for UVB protection [84], 
while oxybenzone is used as a UVA absorber [84]. Microfine zinc oxide (ZnO) and 
 Vitamin A 
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titanium dioxide (TiO2) are two most widely used inorganic UV absorbers in sunscreens 
[85]. In the study of new molecules related to UV protection, one Japanese group 
demonstrated that the transferrin receptor (TfR) was 2-fold higher in UV resistant cell 
line UV
r
-1 vs. in control human fibroblast cell line RSa. Anti-TfR antibody can diminish 
the UV
r
-1 resistance to UV. Furthermore, overexpression of TfR led to UV resistance in 
normal human fibroblast cell RSa and COS7 cells.  It has been suggested that TfR might 
be related to photoaging protection, and its expression impart UV resistance [86].  
 
4. Remediation of UV induced skin damage 
In contrast to protection, remediation of skin photoaging is less developed. As we 
mentioned, retinoic acid or its metabolites can stimulate new collagen formation and 
deposition, which in turn can improve damaged skin [79-82]. The published data also 
suggest that Vitamin C might act to reduce DNA damage and facilitate DNA excision 
repair, as well as suppressing inflammation and cell proliferation [87]. For instance, 
topical vitamin C has been shown to prevent erythema and sunburn cell formation and 
up-regulate collagen production, while a 6-month randomized, double-blind, placebo 
controlled study showed a significant decrease in wrinkles [88]. Topical coenzyme Q10 
is another antioxidant; a 6-month pilot study showed a significant reduction in wrinkle 
measurements [71,88]. An oral supplement containing l-proline, l-lysine, manganese, 
copper, zinc, quercetin, grape seed extract, N-acetyl D-glucosamine, and glucosamine 
sulfate improved wrinkles by 34% in a pilot study [88]. Another oral supplement, 
containing vitamin E, vitamin C, carotenoid, selenium, and proanthocyanidin, led to a 
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significant decrease in MMP production after UV exposure. A reduction in UV-induced 
erythema was also noted, but did not reach statistical significance [88].  
The other remediation treatment in use is carbon dioxide laser resurfacing. 
Briefly, imitating the natural course of wound healing, the process relies on degrading the 
fragmented collagenous matrix followed by the natural immune response to healing 
which would be rebuilding new collagenous matrix [89,90]. Other remediation methods 
include dermal fillers, such as cross-linked collagen and cross-linked hyaluronic acid. 
These injected fillers can stretch skin and create a smoother skin surface, and possibly 
also stimulate fibroblasts to produce more collagen and less MMPs [91].  
 
5. UV and skin cancer 
Globally, there are an estimated 2.5 million non-melanomas skin cancers 
diagnosed each year [92]. Non-melanoma skin cancer (NMSC) including squamous cell 
carcinoma (SCC) and basal cell carcinoma (BCC) have shown a dramatic increase in 
Caucasians in the last decades, which are thought as  the most common malignancy in 
white populations [93]. Experimental and epidemiological studies have pointed the 
attention to sun light as the most important environmental risk factor in the development 
of skin cancer. Chronic sun exposure can cause approximately 90% of the one million 
new cases of NMSC diagnosed each year in the United States. 84% of BCC and 74% of 
SCC are found at chronically sun exposed body sites [93,94]. It is now generally accepted 
that chronic exposure of UV radiation can cause and promote cancer development on 
skin through two major mechanisms: 1) direct interaction with DNA leading to code 
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mutations of the genome, and 2) alteration of the immune system [95]. UVB was initially 
considered the most biologically important part of UV in photocarcinogenesis. However 
there is now evidence that UVA also plays an important role in the mutational effects of 
solar light [96], which is implicated in the immunomodulatory effects of UV on human 
skin [97,98]. 
UVA and UVB radiation are proved to produce DNA damage directly and 
indirectly through oxidative stress. The most cytotoxic and mutagenic wavelength among 
the various types of solar radiation is UVB light. UVB is demonstrated to be the most 
effective light to induce skin cancer in animals by damaging DNA, particularly 
cyclobutane pyrimidine dimers (CPDs) and photoproducts which induce mutations in the 
epidermal cells and lead to the development of cancer cells. Among CPDs, thymine-
/cytosine (TC) and Cytosine-cytosine (CC) dimers are shown to be the most mutagenic.  
Although DNA is not a chromophore for UVA radiation [99], it could be damaged by 
UVA induced ROS. Electron transfer or singlet molecular oxygen produced by UVB and 
UVA radiation could target DNA base guanine, giving rise to 8-hydroxydeoxyguanosine 
(8-OHdG) in the strand DNA, which is a miscoding lesion causing G to T transversion 
[103]. 
DNA damage leads to the altered expression of various gene products implicated 
in protective or reparative processes such as apoptosis, genomic repair and growth arrest. 
P53 is the most studied of these genes. The tumor suppressor gene p53 plays an important 
role in skin carcinogenesis, and the interruption of p53-mediated apoptosis appears as a 
necessary step in UV-induced carcinogenesis [100]. The gene of p53 is a direct target of 
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UV radiation, and specific mutations were identified in the coding sequence; TC→TT 
and CC→TT mutations are frequently found in the p53 gene of UV-induced cancer cells 
[100].This is a gene involved in the regulation of the cell cycle and it has been shown that 
there is a direct relationship between the UV induced mutations on p53 and the 
development of squamous cell carcinoma [101]. For basal cell carcinoma this relationship 
is present as well, but not so striking [102]. P53 mutations critically contribute to 
uncontrolled cell proliferation and lack of apoptosis. The important role of p53 
inactivation is also clearly seen in p53 knockout mice, which develop skin tumors much 
earlier than their wild-type counterparts upon UV radiation [101].  
The epidermal growth factor receptor (EGFR) is another well known molecule 
related with skin carcinogenesis. EGFR, also known as human epidermal growth factor 
receptor1 (HER1) or c-ErbB-1, belongs to the ErbB family of receptor tyrosine kinases, 
which are involved in neoplastic growth [104]. This receptor is overexpressed in many 
human cancers, including colorectal cancers and SCC of the head and neck [104,105]. 
EGFR has been targeted by systemic drugs of various mechanisms, including cetuximab, 
a monoclonal antibody that binds to the extracellular ligand domain, and gefitinib and 
erlotinib, chemicals that bind the adenosinetriphosphate - binding site.  All three drugs 
act to prevent tumor growth by inhibition of the EGFR-mediated signaling cascade, 
resulting in stimulation of apoptosis of cancer cells [106-108].  
Rapid UV induced EGFR activation in the epidermis appears to depend on ROS 
generation rather than on ligand interactions [109]. Thus, receptor-type protein tyrosine 
phosphatase j (RPTPj) becomes an important negative regulator of EGFR, which keeps 
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EGFR in its unphosphorylated and inactive state. UV-induced ROS leads to oxidative 
inhibition of RPTPj, which causes the activation of EGFR [110]. Also Src kinase is 
activated by UV and translocates to the cell membrane, where it may contribute to EGFR 
activation [111]. EGFR has been shown to mediate different UV-induced signal 
transduction pathways, which enhance keratinocyte proliferation and suppress apoptosis 
[112]. The significant role of EGFR activation is also seen in mouse models, where 
pharmacological inhibition of EGFR suppresses UV-induced skin tumors [115]. 
Furthermore, ROS are also shown to activate transcription factors, such as AP-1 
and NFκB, which may contribute to cell proliferation and/or apoptotic cell death. For 
instance, activated AP-1 has been shown to enhance phosphorylation of the c-Jun NH2-
terminal activation domain. JNK1 is activated by dual phosphorylation at Thr and Tyr 
during UV response, binds to the c-Jun transcription domain and phosphorylates it on 
Ser-63 and Ser-73. This process is thought to be responsible for UV-induced tumor 
promotion [116].  The other groups show that once JNK and p38 are activated, p38 may 
drive a positive feed-back loop via Rac1 and NADPH oxidase (NOX) which will lead to 
further ROS generation [113,114]. 
The skin used to be thought as just a passive barrier. However it is now clear that 
is an active part of the immune system since the discovery of T lymphocytes homing in 
the skin [117]. In 1974 Kripke further demonstrated that UV induced tumors grew in 
immunocompromised hosts and that UV radiation caused systemic immunosuppression 
through UV-induced T suppressor cells [118]. Since then the basis of modern 
photoimmunology was estabilished. In 1978, Streilein recognized the importance of skin 
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as an immunologically relevant organ, [119] and coined the term SALT “skin associated 
lymphoid tissue” which later became “SIS”: Skin Immune System [120]. SIS is 
composed of different cell populations: keratinocytes (KC), monocytes, epidermal 
homing T cells, skin free nervous fibers, dermal macrophages and Langherhans cells 
(LC). These cells communicate and interact through a complex network of soluble 
mediators such as prostaglandins and cytokines that allow the initiation of the immune 
response and performance of immunosurveillance [121]. KCs are a larger reservoir and 
powerful producers of many cytokines, some of which could be involved in UVB 
induced immunosuppression.  
UVB is also known to suppress immune reaction, and induce tolerance to 
antigens. UV-induced immunosuppression is studied by two models: local and systemic. 
In the “local immunosuppression”model:  the site of hapten application corresponds to 
the site of UV irradiation thus resulting in an impaired contact hypersensitivity reaction 
(CHS) and formation of antigen-specific T suppressor cells. The mechanism of immune 
disregulation is mediated directly through UV induced alteration in the APC function. In 
the “systemic immunosuppression” model: the site of hapten application is far from the 
irradiation site. Immunosuppression circulating cytokines or factors is involved since 
there is no direct contact between UV irradiated APC and hapten. Cytokines implicated 
include: Interleukin-1, 10, 12 (IL-1, IL-10, IL-12), Tumor necrosis factor alfa (TNF-α) 
and Tumor Growth Factor-beta (TGF-β) [122-126]. For instance, one group reported that 
skin tumors developed in adult mice exposed to high dose of UVB radiation were 
rejected when transplanted to syngenic healthy mice, but continued to grow when 
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transplanted to mouse skin pre-exposed to UVB radiation before tumor cell 
transplantation. Further, mice chronically exposed to UVB radiation displayed a systemic 
defect in antigen presentation [127]. The others reported that skin exposed to low doses 
of UVB radiation had diminished ability to respond to hapten painted on irradiated skin 
sites [128]. Interestingly, that unresponsiveness could be transferred with viable 
lymphocytes to naive recipients, which indicated that suppressor T cells might play the 
role [129]. The mechanisms of local immunosuppression are complex and could be 
related to a number of components including a direct effect on the antigen presenting 
activity of LCs and other antigen presenting cells like dermal macrophage in the skin 
[130], local production of immunomodulatory cytokine such as TNF-α [131], or the 
infiltration of macrophages into the skin which have different antigen presenting 
capabilities from the normal resident APC [132].  In the case of suppression of the 
delayed hypersensitivity reaction (DTH) response to herpes virus injected locally into 
UV-irradiated skin sites [133], the isomerization of urocanic acid to its 
immunosuppression cis-isomer is thought to be responsible [135]. In systemic 
immunosuppression, it is suggested that DTH could be modulated by IL-10, possibly 
released from UV-irradiated KCs, and contact hypersensitivity reaction (CHS) might be 
modulated by TNF-α, since antibodies against IL-10 and TNF-α suppress DTH and CHS 
respectively [135]. 
The photoreceptors directly interact with UV and represent the initial target for 
UV in the skin.  There are two most important photoreceptors in the skin: Urocanic Acid 
(UCA) and DNA. UCA is one of the major UV absorbing components in the stratum 
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corneum. It is produced during the process of keratinization and undergoes a trans to cis 
isomerization after interaction with UVB [136]. Its role in UVB immunosuppression has 
been first postulated by Noonan and DeFabo [137] when they demonstrated that the 
removal of the stratum corneum prevented UV interaction with skin. Several studies 
support the role of cis-UCA as one of the mediators of UVB-induced 
immunosuppression. For instance, the intradermal injection of cis-UCA in animal models 
induces a dose dependent suppression of the DTH [138] and suppresses CHS [139]. Cis-
UCA also changes splenic dentritic cells‟ APC function, indistinguishable from the one 
induced by UVB irradiation [140]. Moreover topically applied Cis-UCA raised the 
incidence of UVB induced tumors in animals [141]. 
DNA is another molecule that strongly absorbs UV. The effect of UV radiation on 
DNA mutations has been discussed as above. UVB induced cis-UCA and cyclobutane 
pyrimidine dimers (CPD) ultimately mediate their immunosuppressive properties through 
impairment of the function and decrease of the number of immunocompetent cells in the 
skin, providing a reduced immunosurveillance environment for the tumor growing [142].  
Langerhans cells (LC) are the principal target of UV effects. LCs represent the most 
important APC cell of the skin and are required for the initiation of the immune response 
[143]. UV irradiation has been shown to reduce the number of LCs in the skin [144] and 
alter their morphology such as reducing dendritic processes of LCs [145]. The drastic 
decrease in APC number seems to be important for UV-induced immunosuppression only 
in inducing phase of the cellular immune response since depletion of LC during the 
elicitation phase causes an enhancement of the CHS response in mice [146]. UV radiation 
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also reduces LC‟s ability to present tumor associated antigens (TAA) after priming with 
Granulocyte/macrophage colony stimulating factor (GM-CSF) [147], and this 
fundamental capacity is inhibited by UVB [148] probably through an IL-10 mediated 
mechanism [149]. It has also been demonstrated that one of the major effects of UV on 
LC is to cause LC unable to prime Th1 lymphocytes and thereby promoteing anergy, 
while UV doesn‟t affect the LC‟s function on Th2 cells. Therefore, this mechanism helps 
develop tolerance [130].  
There is increasing evidence that UV-induced regulatory T cells (Tr) play an 
important role during photocarcinogenesis, because they are able to inhibit anti-tumor 
effector function [150]. Recently it has been demonstrated that failed antigen presentation 
is the result of those induced Tr type 1 which produce high amounts of IL-10, a cytokine 
that plays a pivotal role in the mechanism of UV immunosuppression. Indeed IL-10 is a 
cytokine that has a profound impact on skin immunity and tumor immunosurveillance: 
invasive basal cell carcinomas have been shown to secrete high levels of this cytokine 
[151] and IL-10 levels in melanoma have been directly correlated with a bad prognosis 
[152]. 
During the uncontrolled proliferation of melanocytes, the consumption of oxygen 
and nutrients will dramatically increase and eventually lead to cell starvation and 
hypoxia. To fulfill this increasing demand, additional vasculature needs to be developed. 
Thus, to increase the blood supply, the tissue begins to produce a spectrum of growth 
factors that trigger the process of angiogenesis. Angiogenesis is the process of formation 
of neovasculature from pre-existing blood vessels and is widely considered to be an 
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essential process to ensure the supply of nutrients and oxygen to rapidly growing tumors, 
as well as to provide a route for tumor cell metastasis [153]. Angiogenesis is a distinct 
feature of several human cutaneous melanomas and was first described by Warren and 
Shubik following transplantation of human melanoma tumor tissue into a hamster cheek 
pouch [154]. Rapid angiogenesis of cutaneous melanomas dramatically enhances the risk 
of lethality and contributes to the progression of the most common type of cancer in 
young adults [154]. As we indicated, tumor vasculature is important for a tumor‟s 
growth, progression, and metastasis to distant sites. Many anti-angiogenic agents are 
currently in clinical trials. Bevacizumab was the first FDA-approved anti-angiogenic 
compound for cancer patient treatment [155].  
Like any other cutaneous neoplasia, melanomas follow discrete sequential 
transformation processes in which the nevus attains a dysplastic radial growth phase. This 
is followed by a vertical growth phase [156]. The vertical growth phase requires high 
angiogenic activity, which, in turn, contributes to melanoma cell metastasis. However, 
the most critical step in metastasis is the spreading of melanomas to lymphatic vessels 
surrounding the tumor tissue. Following or concurrent with lymph node invasion, 
melanoma cells can metastasize to the lung, liver, cerebrum, and other sites, which 
eventually will imperil patient‟s life. 
MMPs have been shown to be the major class of proteases that play crucial role in 
tumor spreading and angiogenesis. Digestion of extracellular matrix by MMPs of 
melanoma or endothelial origin promotes release of matrix bound fibroblast growth 
factor (FGF), which, in turn, stimulates endothelial cell proliferation and vascular tube 
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formation in melanomas [157]. Several studies indicated that the basal level of MMP 
production in benign or normal melanocytes is typically low and expression of MMPs is 
highly correlated with disease progression. MMP activation is accomplished by removal 
of the N-terminal propeptide domain through exogenous or autocatalytic cleavage [157]. 
MMP-2, which is abundantly expressed in early stages of malignant transformation, is 
known to achieve activation in a membrane-associated manner in endothelial cells and 
melanoma tumor cells. Further, cell surface associated membrane-type matrix 
metalloproteinase (MT1-MMP) is also known to activate MMP-2 through this 
mechanism [158]. To date, the most extensively studied MMPs in melanomas are MMP-
2 and MMP-9. It has been demonstrated by several groups that the expression and 
activation of these enzymes is correlated to the invasive and metastatic phenotypes of 
melanomas [159]. Malignant melanoma cells are known to express a number of MMPs, 
including MMP-1,-2, -9, -13, and -14, as well as inhibitors of MMPs such as TIMP-1, -2, 
and -3 [159]. The expressions of MMPs and TIMPs in human skin BCC and SCC has 
been listed in Table 1 (Reproduced from Kerkela and Saarialho-Kere‟s review paper) 
[160]. Increases in expression of MMPs were shown to highly correlate with low survival 
rates in patients with malignant melanoma tumors [160].  
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It also is important to note that not only expression of MMPs, but also their 
functional activity, is required for malignant tumor progression. Genetic overexpression 
of MT1-MMP in melanoma cells induced activation of MMP-2 and this activation is 
crucial for extracellular matrix degradation when localized on the leading edge of 
invasive carcinomas [160]. A clinical study of human melanoma lesions consisting of 
different stages of tumor progression found that MMP-2 and MT1-MMP positive tumor 
cells were often restricted to the interface between the tumor stroma and the invasive part 
of the tumor [160].  Expression of MMPs is not only restricted to tumor cells but also is 
found abundantly in stromal cells. This clearly indicates a major contribution of host-
derived proteases to melanoma tumor progression. One of the major MMPs found to be 
expressed in human melanoma is MMP-1[161]. A series of studies has also indicated that 
MMP-1 expression is highly associated with malignant melanoma progression. In vitro 
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studies indicated that degradation of collagen types I and IV and tumor cell invasion 
through Matrigel required MMP-1 expression. Other than MMP-1 and -2, the major 
MMP expressed in melanoma tumor cells is MMP-9 [162]. MMP-9 expression in 
melanoma tumor cells was found only during the radial growth phase but not during the 
vertical growth phase. This clearly suggests that expression of MMP-9 is an early event 
in melanoma progression.  
Several studies using either model cell lines or animals have demonstrated that the 
balance between MMPs and their inhibitors determines melanoma tumor progression 
[163]. To date, TIMPs are extensively studied as they are natural inhibitors of MMPs and 
hence could be potential therapeutic targets. Numerous conclusive studies demonstrate 
that overexpression of TIMP -1, -2, and -3 significantly reduces melanoma tumor cell 
invasion, migration, tumor growth, and metastasis [164]. And several studies in tumor 
models have indicated that TIMPs significantly reduce tumor neovascularization. 
However, although TIMPs are known to inhibit tumor cell metastasis in several 
experimental animal models, TIMPs have been found to significantly enhance tumor cell 
proliferation in human melanoma cells [165]. Therefore, the role of TIMPs in melanoma 
tumor growth is still not clear.  
As MMPs are known to play crucial roles during the processes of tumor 
progression, in the early 1990s, MMP inhibitors generated great enthusiasm among 
several research groups wishing to take them to clinical trials. Preclinical trials of MMP 
inhibitors were very promising, showing minimum side effects compared to other drugs 
available at that time. Most of inhibitors, which have been tested in preclinical and 
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clinical trials, were broad category MMP inhibitors. For instance, pharmacological 
inhibitors such as batimastat and its analog marimastat, which interfere with the catalytic 
site of the MMPs, were the first inhibitors studied in detail. Unfortunately, most of those 
MMP inhibitors tested in clinical trials were not very promising due to the lack of 
positive outcomes and the appearance of substantial drug side effects, which were not 
observed in preclinical studies. Therefore, the clinical trials for most of them were 
terminated following phase III clinical trials. This failure of early MMP inhibitor clinical 
trials substantially suppressed the initiation of new clinical trials of MMP inhibitors 
targeting cancer [166, 167]. 
Currently, only two types of drugs used in skin cancer treatment, epidermal 
growth factor receptor (EGFR)-targeted drugs and fluorouracil, have been recommended 
by the US FDA and European Medicines Agency (EMEA) for pharmacogenetic testing 
[104,105,168]. The importance of EGFR in UV induced skin cancer has been discussed. 
Fluorouracil is a pyrimidine analog.  The incorporation of the fluorouracil metabolites 
into nucleic acids results in decreased RNA synthesis, stability, and processing, and 
decreased DNA elongation and replication, resulting in cell-cycle arrest and apoptosis, 
which can suppress tumor growth [108]. 
 
6. Mitogen-activated protein kinases (MAPKs) and UV induced signal pathway 
Much recent work has indicated that mitogen-activated protein kinases (MAPKs) 
play a significant role in mediating UV induced biological effects. MAPK signaling 
becomes the key signal pathway trigged by UV [20]. MAPKs are a family of proteins 
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which include the extracellular signal regulated kinases (ERKs), p38 kinase, and c-Jun 
NH2-terminal kinase (JNKs). ERKs has two isoforms (1/2); p38 kinase has four isoforms 
(α/β/δ/γ); JNKs has three isoforms (1/2/3) [169]. In normal conditions, MAPKs mediate 
several cellular and organismal functions including proliferation, growth, differentiation, 
development, and apoptosis. Under stress conditions such as UV stimulation, many data 
have demonstrated that MAPK signaling is very important for protecting skin and 
allowing it to resist UVR induced skin damage and carcinogenesis by activating cell 
cycle arrest, apoptosis, and inflammation in those damaged tissues [170]. After cell 
surface receptors such as EGFR (epidermal growth factor receptor) become stimulated by 
UVR, MAPKs are activated by dual phosphorylation on threonine and tyrosine at 
Threonine-X-Tyrosine motifs within their activation loop. One or more MAPK kinase 
(MAPKKs) catalyzes this phosphorylation, and they themselves are activated by 
MAPKK kinases (MAPKKKs). Besides the cell surface receptor induced MAPKKK-
MAPKK-MAPK pathway, MAPKs also can be activated through the Ras family of G 
proteins. After Ras is activated, it will initially induce cell proliferation, targeting 
MEK1/2 MAPKK activation. Those activated MAPKK further activate ERK1/2 which 
can induce the AP-1 transcription factor that is important to cell proliferation. However, 
Ras-MEK-ERK will also activate p38 and increase the expressions of p53 and p16 which 
have anti-proliferative function [171,172].  
Regarding UV mediated signaling, some differences have been found between 
signaling induced by UVA and UVB. It was thought that UVA first might phosphorylate 
EGFR. Then it would activate several downstream effector molecules, including the 
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phosphorylation of p70
S6K
 and p90
RSK
. These two phosphorylated proteins further 
phosporylated the 40S ribosomal protein S6. UVA might also activate the JNKs, ATM 
(ataxia telangiectasia mutated) and SMase (sphingomyelinase) which would lead to 
apoptosis [173]. In contrast to UVA mediated signaling pathway, UVB may activate the 
MAPKs by stimulating EGFR and/or PKC (atypical protein kinase C). UVB can also 
activate the PI3K (phosphatidylinositol 3-kinase) pathway which can further activate 
many downstream molecules such as Akt (also called protein kinases B). Generally 
speaking, JNK and p38 MAPKs are activated by stress stimulations such as UVR while 
ERKs are activated by mitogenic stimuli [170]. However, just as indicated above, there 
are some cross talks among these three MAPKs. In the skin, many results have 
demonstrated that MAPKs play an important role in regulating several key oncogenes 
and tumor suppressors that are relative to UV induced cancers including p53, p16, 
APC/β-catenin, and Ha-ras. JNK and p38 are thought to block cell proliferation or 
promote cell apoptosis by modulating p53; apoptosis would be impaired in the absence of 
JNK and p38 [174,175]. For instance, it was found that p38 inhibitor SB202190 blocked 
the UV induced apoptosis in mouse skin. P38 could phosphorylate Ser33 and ser37 of 
p53, while the Ser15 of p53 could be phosphorylated by p38 and ERK, and JNK 
phosphorylated Ser20 of p53 [174-176]. The MAPKs involved in apoptosis are a very 
essential and effective way to protect and eliminate UV induced skin cancer and damage, 
which is known to be very important for preventing tumors. MAPKs are not only 
involved in apoptosis but are also required by the UV induced inflammation or erythema.  
Keratinocytes are the major cells to release cytokines in the epidermis. After UV 
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radiation, they secrete many cytokines, such as granulocyte colony-stimulating factor (G-
CSF), IL-3, IL-6, IL-8, macrophage-CSF, transforming growth factor α/β (TGF α/β), 
platelet-derived growth factor (PDGF), GM-CSF, interferon gamma (INFγ). These 
cytokines can further attract Langerhans cells and activate neutrophils, macrophages and 
fibroblasts. MAPKs have been shown to regulate all those cytokines‟ expression [177-
178]. 
7. Spleen tyrosine kinase (Syk) and MAPKs  
Syk is a 72 KD protein, and was originally cloned from porcine spleen in 
1991[179]. The human Syk locus has been mapped to chromosome 9 at band q22 [180]. 
Syk contains two tandem SRC homology 2 (SH2) domains and a carboxy‑terminal 
tyrosine kinase domain (Fig.1.2). These domains are connected by two linker regions: 
interdomain A between the two SH2 domains and interdomain B between the C‑terminal 
SH2 domain and the kinase domain. An alternatively spliced form of Syk (known as 
Syk‑B) lacks 23 amino acids of interdomain B, including a nuclear localization signal 
[181]. The kinase domain of Syk is in the resting state of the protein. And Syk can be 
activated and expose the kinase domain by binding of both SH2 domains to dually 
phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs). 
Phosphorylation of tyrosine residues in the linker regions (interdomain A or B) also 
results in kinase activation even in the absence of phosphorylated ITAM binding. It has 
been confirmed that Syk can be activated by either deletion of both SH2 domains, or of 
interdomain A alone, as well as binding of a phosphorylated ITAM to the SH2 domains.  
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Syk also can catalyze the autophosphorylation of its linker region tyrosine residues, 
leading to sustained Syk activation after transient ITAM phosphorylation. In addition, 
Syk itself can phosphorylate ITAMs, suggesting the existence of a positive feedback loop 
during initial ITAM‑mediated Syk activation [181]. Syk activation can be inhibited by 
phosphatases such as SH2 domain‑containing protein tyrosine phosphatase 1 (SHP1) 
[182]. The expression of Syk is also negatively regulated by the E3 ubiquitin ligase 
Casitas B‑lineage lymphoma (Cbl), which causes ubiquitylation and degradation of Syk 
[183]. 
Syk has been long thought to be a hematopoietic cell-specific signaling molecule, 
which is expressed by all hematopoietic cells such as macrophages, neutrophils, 
monocytes, NK cells, platelets, B cells, T cells, eosinophils, and mast cells [181]. Syk 
plays an important role in lymphocyte development and antigen receptor signaling. It can 
be found throughout B cell development. Knocking out the Syk gene destroys B cells 
differentiation from the pro-B to pre-B and the maturation from immature B cells to 
circulating B cells [181]. Syk also plays critical roles in TCR signaling [181], and FcγRs 
signaling. It was shown to be very important for FcγRs mediated phagocytosis in 
macrophages, monocytes and neutrophils [181]. It is also critical for neutrophils to 
generate reactive oxygen intermediates in response to FcγR engagement [184]. Recent 
studies have demonstrated that Syk is also expressed by many non-hematopoietic cells. 
Coopman and colleagues evidenced its expression in normal and tumorigenic mammary 
epithelial cells [185]. Wang and Malbon first demonstrated that Syk was expressed in the 
mouse embryonic fibroblast cell line 3T3-L1 [186]. The data from Yamada‟s group 
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indicated that Syk can be found in human nasal fibroblasts [187].  Interestingly, the same 
group further studied the effect of Syk on the activations of JNK, P38 and ERK in human 
nasal fibroblasts. Their results suggest that the IL-1 induced phosphorylation of JNK and 
P38 but not Erk was enhanced by increased Syk expression. This finding was further 
confirmed by their results in highly Syk expressing human nasal fibroblasts, where the 
IL-1 induced phosphorylation of JNK and P38 was decreased in the presence of Syk 
antisense which blocks Syk expression [188]. Although the expression of Syk is tightly 
regulated, the mechanism of this regulation, and that leading to the generation of the 
Syk‑B isoform, is not well understood. Mammals also express the Syk‑related molecule 
δ‑chain‑associated protein kinase of 70 kDa (ZAP70), which is mostly found in the T 
and natural killer (NK) cell lineages. There are ten tyrosine residues in Syk that are sites 
of autophosphorylation, most of which have been shown to be important in regulating 
enzymatic activity or participate in Syk-mediated signal transduction. Phosphorylation of 
Y317, Y342 and Y346 is dependent on the SRC-family kinase Lyn; phosphorylation of 
Y130, Y519 and Y520 is dependent on SYK itself which may be sites of auto-
phosphorylation; phosphorylation of Y290, Y358, Y624 and Y625 has only been 
demonstrated in vitro [181]. The Syk gene has been disrupted in mice. The major 
phenotypes displayed by Syk‑deficient mice are perinatal lethality, a petechiated in utero 
appearance and the lack of mature B cells [189]. Two groups have also reported 
mutations allowing the Cre-mediated conditional deletion of Syk [190]. So far, there are 
no human patients or animal strains with a spontaneous germline mutation in SYK have 
been described. 
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 Figure 1.2. Schematic structure of SYK/ZAP-70 family protein tyrosine kinases.  
Immunology Today 2000, 21:148-154. 
 
Given the importance of Syk in immune cell signaling, a number of small drug 
inhibitors have been developed in an effort to suppress the autoinflammatory response in 
diseases. The Syk inhibitor R406 potently inhibits IgE- and IgG-mediated activation of 
Fc receptor signaling and reduces immune complex-mediated inflammation [191]. The 
R788, an oral prodrug of R406 that is rapidly converted to a potent and relatively 
selective inhibitor of Syk (R406), claims the same effects [192] and has been considered 
in the treatment of allergic and autoimmune diseases including arthritis and SLE [193]. 
More excitingly, Rigel Pharmaceuticals, Inc located in South San Francisco, CA 
announced that its oral Syk kinase inhibitor, R788 (tamatinib fosdium), has been shown 
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to have  acceptable side effects and significant clinical improvement in a Phase II clinical 
trial in patients with rheumatoid arthritis [194]. Before that happened, Pfizer had invested 
$5 million as a milestone for the study of Syk inhibitor R343 in treating allergic asthma 
and chronic obstructive pulmonary disease in Rigel Pharmaceuticals, Inc [195]. Recently, 
more and more studies have shown that Syk could be a potential marker for tumor 
formation and progression. Coopman et al found Syk expression in both normal human 
breast tissue and in low-tumorigenic breast cancer cell lines. However, lower and 
undetectable Syk was found in invasive breast carcinoma tissue and cell lines. More 
interestingly, overexpression of Syk can suppress tumor cell growth and metastasis 
formation [185]. This result has also been confirmed by the data from Toyama‟s group. 
Their results have shown that patients with reduced Syk expression would have the 
higher risk for distant metastasis [196]. Wang and colleagues also determined that Syk 
expression was lower in gastric cancer patients with lymph node metastasis vs. those 
patients without lymph node metastasis [197]. However, the results from Thompson‟s 
group demonstrated that Syk was overexpressed in anaplastic large cell lymphoma 
(ALCL) which is a very aggressive large T- or null-cell lymphoma which usually 
expresses anaplastic lymphoma kinase (ALK) [198]. These observations in cancer 
research suggest that there is a link between malignant formation/progression and Syk 
expression/activation. They also indicate that Syk could be a potential candidate for 
development of cancer therapeutics. 
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Chapter 2 
 Possible effect of Syk kinase on the UV induced signaling 
 
Syk kinase is expressed by all hematopoietic cells. It plays critical roles in 
lymphocyte development and signal transduction via immune receptors in immune and 
non-immune cells. Syk kinase contains two Src homology 2 (SH2) domains in tandem, 
and multiple autophosphorylation sites. Through its SH2 domains, Syk binds with 
immunoreceptor tyrosine-based activating motif (ITAM) in the cytoplasmic domain of 
those cell surface receptors [181]. After Syk is activated, it will further stimulate its 
downstream molecules. Many Syk substrates and downstream molecules have been 
found, including SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa), BLNK 
(B cell linker protein), Shc (Src homology and collagen), LAT (linker for activation of T 
cells), Vav1 (guanine nucleotide exchanging factor for rac), Cbl (product of 
protooncogene c-cbl), PLC-γ (phospholipase C-γ), PI3K, MAPK and et al [199].  
Although no published data indicated that Syk was involved in UV induced skin damage, 
as we indicated, recent studies had demonstrated that Syk was also expressed by many 
non-hematopoietic cells including  epithelial cell, vascular endothelial cells, melanocytes 
and neuron-like cells, mouse embryonic fibroblast cell line 3T3-L1, and human nasal 
fibroblasts as indicated in chapter 1. Not only that but also a critical role of Syk in 
activation of MAPKs is well characterized [200]. For instance, it had been shown that 
Syk was required for FcεRI-induced ERK and JNK activation in mast cells [200,201]. 
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And LAT, a Syk adaptor molecule, was also found to involve in immune receptor-
mediated ERK and JNK activation. In T cells, the data showed that Syk and Rac1 
cooperated in synergistic activation of JNK. In B cells, BLNK, another adaptor molecule 
of Syk, was important for coupling Syk to Rac-JNK pathway [199]. Evidence also 
showed that the phosphorylation of Tyr
342
 in the linker region of Syk was a docking site 
for SH2 domain of Vav1, which was important for Vav1 translocation [199]. Vav1 
translocation and its interaction with LAT, SLP-76 and Rac1 are essential for JNK 
activation [199]. In addition, p38 MAPK activation could not be found in Lyn and Syk 
double deficient cells [199].  Although the role of Syk in UV stimulation is not clear, it 
has been determined that Syk is activated and tyrosine phosphorylated following stress 
stimulations such as H2O2 treatment [202]. Syk was also found to be important for JNK 
activation following oxidative stress [202]. Furthermore, it has been shown that Syk is 
required in B cells for the activation of the PI3K-Akt pathway induced by oxidative stress 
[203]; Akt can phosphorylate caspase-9 to inhibit its protease activity and resists 
oxidative stress induced apoptosis [203]. Based on these current studies, it is well known 
that MAPKs are thought to be key players in UV induced signal transduction pathways 
[20]. Although so far there are no data to show the effect of Syk kinase on UV mediated 
signaling and damage, it has been well demonstrated that Syk plays an essential role on 
MAPK activation under other stimulation condition [200].  Recently, Syk also has been 
found in the synovium of patients with rheumatoid arthritis.  It has been shown that 
activation of Syk is important for cytokine (IL-6) and metalloproteinase (MMP-3) 
production induced by tumor necrosis factor α in fibroblast-like synoviocytes from those 
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patients [204]. Therefore, we hypothesize that Syk could be a new and key target for the 
study of UV mediated signaling pathway and skin photodamage.   
 
 
 
Figure 2.1.  UV induced signaling pathways and possible relationships with Syk kinase. 
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Chapter 3: Significance and specific aims 
 
            There is no easily accessible molecular indicator for the level of skin UV damage 
and its correlation to development of skin cancer. Many known changes in matrix 
metalloproteinases occur only after very prolonged UV exposure and damage and as such 
are not useful early indicators that could be used as warning signs. The efficacy of 
cosmeceutical skin treatments promoted to protect or repair damage is based on visual 
subjective comparisons with no underlying biochemical correlates. There is an unmet 
need to quantify the benefit of such treatments both for development of better ones and 
for acceptance by the consumers. On the other end of the spectrum, there is need to 
understand and predict progression of skin damage to skin cancer, and biomarkers that 
would prove valid indicators can be translated into high volume lab tests.  
This research aims to evaluate the sensitivity and usefulness of Syk (spleen 
tyrosine kinase) as an early indicator of skin UV damage and therefore a valuable 
preventive or therapeutic target of such damage. Our specific aims are: 
Aim1: Determine Syk kinase expression and activity in response to UV exposure, in vitro 
and in vivo. 
 In Vitro: 
 Determine the effect of UV exposure on Syk mRNA in human dermal 
fibroblasts and keratinocytes.  
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 Quantify Syk activation after UV exposure in human dermal fibroblasts. 
 In Vivo:  
 Compare Syk expression in the skin of hairless mice with vs. without UV 
exposure. 
 Compare Syk expression in human skin samples: normal vs. photodamaged 
skin. 
Aim 2: Evaluate the effect of Syk kinase on known markers of UV damage, in vitro and 
in vivo. 
 In Vitro: 
 Evaluate the effect of Syk on key photo-damage molecules such as MMP-1. 
 Study the effect of Syk on the activation of its downstream molecules 
(MAPKs) in human dermal fibroblasts with UV exposure.  
 In Vivo: 
 Determine the correlation between Syk and MMP-13 in the skin of hairless 
mice with UV exposure. 
Aim 3: Evaluate the effect of Syk kinase inhibitors on known markers of UV damage. 
 In Vitro: Evaluate the effect of a Syk kinase inhibitor on key photo-damage mediator-
MMP-1 in human dermal fibroblasts and keratinocytes. 
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 In Vivo: Study the effect of a Syk inhibitor on MMP-13 expression in the skin of 
hairless mice.  
 
 
 
 
39 
 
Chapter 4: Materials and Methods 
 
1. Antibodies and inhibitors 
The following antibodies were used in this study: MMP-1 and MMP-13 
antibodies (Calbiochem, UK), Syk and -actin (Abcam Inc., Cambridge, MA and  Santa 
Cruz Biotechnology Inc., Santa Cruz, CA), phospho-JNK, phsopho-p38, phospho-Erk1/2 
and JNK (Cell Signaling Technology, Danvers, MA), phosphotyrosine (Millipore, 
Billerica, MA), filaggrin antibody (Abcam, Inc., Cambridge, MA) and inhibitors: 
piceatannol, PP2, Wortmannin, Bisindolylmaleimide l (Calbiochem, UK ). 
2. Cell culture, transfection and UV treatment 
Human dermal fibroblasts AG04058 (Coriell Institute for Medical Research, 
Camden, NJ) and human dermal keratinocytes CRL-2309 (ATCC) were respectively 
cultured and maintained in MEM and DMEM medium containing glucose (4.5 mg/ml), 
glutamine (2 mM), streptomycin (100 U/ml), penicillin (100 g/ml), and 10% heat-
inactivated fetal bovine serum. For cell transfection, Fugene 6 transfection kit (Roche, 
Germany) was used to deliver Syk cDNA and the Saint-Red siRNA delivery system 
(Synvolux Therapeutics B.V., The Netherlands) was chosen to transfect Syk siRNA and 
control siRNA (Santa Cruz Biotechnology Inc., Santa Cruz, CA) into the cells. Cells 
were exposed to UVB (312 nm) (60 mJ/cm
2
) by a Stratalinker UV Crosslinker 
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(Stratagene, La Jolla, CA). Cell culture media were collected 24 hrs after UV exposure, 
and prepared for MMP-1 expression assay. 
3. Animal experiments and UVR treatment 
The SKH1 hairless mouse is a well established animal model to study UV-
induced damage in skin [205]. SKH1 female albino hairless mice were obtained from 
Charles River Laboratory (Wilmington, MA), allowed to acclimatize for a week before 
the start of the experiments, then randomly separated into two groups. Animals in UV 
treated group were exposed to UVR three times a week at the dosages shown in Table 
4.1. The Solar Simulator used has a spectral output of 97% UVA and 3% UVB [206], 
which is similar to that of solar UV radiation. At the end of 5 and 10 weeks, animals were 
sacrificed, and UV exposed and unexposed skin samples were removed and subjected to 
flash-freezing in liquid nitrogen. The samples were used for further western blot assays. 
Week Weekly dose 
of UVB 
Cumulative 
dose at the 
end of the 
experimental 
period 
Weekly dose 
of UVB 
(mJ/cm2) 
Daily dose 
of UVB 
(three times 
per week) 
Daily dose of 
UVB 
(mJ/cm2) 
1 1 MED 1 MED 5 0.33 MED 1.67 
2 2 MED 3 MED 10 0.67 MED 3.33 
3-5 or 10 3 MED 12 or 27 MED 15 1 MED 5 
 
Table 4.1. Procedure and dosage of UV exposure in SHK1 hairless mice. 
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4. Treatment of piceatannol in hairless mice (SKH1) 
The study was performed with three groups of female SKH1 Hairless mice, with 5 
animals in each group. The groups are listed in table 4.2. The SKH1 hairless mice in 
group 3 were treated with 200ul of the piceatannol formulation 2 hours before every 
scheduled UV exposure. The formulation consisted of piceatannol dispersed in a carrier 
cream at a concentration of 250µg per milliliter. The carrier cream consisted of Avicel 
and Protanal® purchased from FMC BioPolymer (Philadelphia, PA) mixed in water, to 
achieve a non-runny consistency. The concentrations of Avicel, Protanal® and water 
were 1gm, 0.66gm and 20ml respectively. 50ul of the formulation was given to each of 
the four areas that were to be exposed and smeared using a cotton swab. They were 
exposed to solar simulated UV light after two hours. The animals were sacrificed at the 
end of 10 weeks and their skin was harvested. 
Group Details Exposure/treatment 
Group 1 Negative control No exposure 
Group 2 Positive control Exposed according to 
protocol in table 1 
Group 3 Piceatannol Exposed according to 
protocol in table 1/ treated 
with piceatanol 
 
Table 4.2.  SKH1 mice grouped in piceatannol effect experiment. 
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5. Immunoprecipitation and immune-blotting 
24 hours after UV exposure, the culture media of human dermal fibroblasts were 
collected for MMP-1 assay. Based on OD280 measurement, equal amounts of proteins 
from the supernatants were mixed with 2×sample buffer, boiled for 5 min and chilled on 
ice. Samples were then subjected to 4-15% SDS-PAGE and electrophoretically 
transferred to nitrocellulose membrane. The membrane was blocked with 5% dry milk in 
washing buffer. MMP-1 was detected with anti-MMP-1 antibody, and the results were 
visualized by an ECL detection system. For Syk protein and MAPK activation western 
blot assays, cell pellets were lysed in 1xTriton X-100 lysis buffer (1% Triton X-100, 5 
mmol/L Hepes–KOH, pH 7.4) in the presence of protease and phosphatase inhibitors 
containing
 
5 mM EGTA, 3 mM Na orthovanadate, 2 mM phenylmethylsulfonyl
 
fluoride, 
and 10 μg/L aprotinin and leupeptin (Sigma Chemical Co., St. Louis, MO). Following 
centrifugation at 12,000 rpm
 
for 30 min at 4°C, the cleared lysates were subjected to the 
same procedure as that followed for MMP-1 assay. Syk protein and MAPK activation 
were detected with anti-Syk antibody and anti-phospho-MAPK antibodies, respectively, 
by western blot. For the activation of Syk kinase assay, briefly, cell lysates were 
precleared by incubation
 
with protein G plus agarose (Santa Cruz Biotechnology, Inc.),
 
and then incubated overnight at 4°C with anti-Syk antibody (4μg). Immune complexes 
would bind to protein G plus agarose in
 
the lysis buffer. The agarose beads were washed 
three times with lysis buffer
 
and the adsorbed proteins were eluted into the sample
 
buffer. 
Tyrosine phosphorylation of Syk kinase (Syk activation) was determined with anti-
phosphotyrosine antibody by western blot. 
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  6. Syk mRNA assay by reverse transcription polymerase chain reaction (RT-PCR) 
For mRNA assay, cells were treated with 300 μl Trizol solution (Invitrogen, 
Carlsbad, CA) for 7 min. After 250 μl chloroform addition, samples were centrifuged at 
12,000 rpm for 20 minutes at 4
o
C. The upper phase was transferred into a new RNase 
free tube and RNA was precipitated by isopropanol for 10 min. After centrifugation at 
12,000 rpm for 15 min, the pellets were washed once with 75% ethanol. The RNA pellets 
were dissolved into DEPC-treated water for further experiments. The RT-PCR assays 
were performed by the Superscript one-step RT-PCR with Platinum Taq kit (Invitrogen, 
Carlsbad, CA). And the procedure followed the manual provided by the manufactures.  
Results were imaged in 1% agarose gel (electrophoresis). PCR conditions: 60 sec 94
o
C 
denature, 60 sec 51
o
C anneal, 90 sec 72
o
C extension. Amplification cycles for PCR 
products: Syk (42); -actin (30).  The primers used for this experiment are as follows:  
Syk forward primer: 
5‟
TTTTGGAGGCCGTCCACAAC
3‟
;
  
 
Syk reverse primer: 
5‟
TGCATGACATTTGCTTCTGCTAAT
3‟
;  
Actin forward primer: 
5‟
 GCTCCGGCATGTGCAA 
3‟
;  
Actin reverse primer: 
5‟ 
AGGATCTTCATGAGGTAGT 
3‟
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7. siRNA knocks down Syk expression 
Either control siRNA or Syk siRNA was transfected into human dermal 
fibroblasts (HDFs) by Saint-Red siRNA delivery system 24 hours after Syk cDNA 
transfection. 24 hours after siRNA transfection, cells were exposed to UVB (60mJ/cm
2
).  
And after another 24 hours cell culture media were harvested for MMP-1 expression 
assay while cell lysates were used for Syk expression determination by western blot.  
8. Syk activity assay 
In order to get enough Syk protein for the assay, human Syk cDNA were 
transfected into human fibroblast cells by Fugene 6 transfection kit (Roche, Germany). 48 
hours after transfection, the cells were further exposed to UV at 60mJ/cm
2
, and lysed in 
1xTriton X-100 lysis buffer (1% Triton X-100, 5 mmol/L Hepes–KOH, pH 7.4) in the 
presence of the protease and phosphatase inhibitors,
 
5 mM EGTA, 3 mM Na 
orthovanadate, 2 mM phenylmethylsulfonyl
 
fluoride, and 10 μg/L aprotinin and leupeptin 
(Sigma Chemical
 
Co., St. Louis, MO). The lysates will be precleared by incubation
 
with 
protein G plus agarose (Santa Cruz Biotechnology, Inc.)
 
and then incubated overnight at 
4°C with anti-Syk antibody.
 
Immune complexes will bind to protein G plus agarose in
 
lysis buffer. The agarose beads will be washed three times in lysis buffer
 
and the 
adsorbed proteins will be eluted into the sample
 
buffer. And tyrosine phosphorylation of 
Syk kinase (Syk activation) will be determined with anti-phosphotyrosine antibody 
(Millipore, Billerica, MA) by Western blot.   
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9. Immunohistochemistry 
a. Deparaffinization:  
  The slides were warmed at 60 
o
C in the oven for 15 min. Place the slides in xylene 
for 5 min twice. Then leave them in 100% ethanol 2 min, 95% ethanol 2 min, 80% 
ethanol 2 min, 75% ethanol 2 min. After that, wash them in 1X PBS for 5 min.  
b. Antigen Retrieval:  
     Immerse slides in 10mM Citric Acid Monohydrate buffer (pH=6), then incubate 
the slides in the steamer (already heated) for 11min. After that, remove the slides from 
the steamer and let it cool for 15min. Finally, rinse them gently in running tap water for 5 
min. 
c. Block with blocking buffer for 15 min: 
      Blocking buffer: 0.1% Tween-20 in PBS + 1% Bovine Serum Albumin (BSA) + 
10% normal goat serum (NGS).  
d. Incubation with primary antibody: 
      The primary antibody concentration used follows the manufacture manual, and is 
diluted in block buffer. The slides are incubated with diluted primary antibody overnight 
at 4 
o
C. In the next day, the slides are rinsed and washed in 1X PBS +0.1% Tween-20 5 
min twice.  
e. Incubation with secondary antibody: 
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      According to manufacture manual, the proper fluorescence labeled secondary 
antibody is diluted in PBT buffer (0.1 M PBS, pH 7.4, 0.1% BSA, 0.2% Triton X-100), 
and incubated with the slides for 60min at 37 
0
C. Rinse and wash in 1X PBS +0.1% 
Tween-20 5min for three times. 
f. Counter staining with Hematoxylin or dapi nuclear staining: 
      Staining the slide with Hematoxylin for 30 seconds, then washing them in running 
water for 5 min. Or adding dapi solution into the slides for cell nuclear staining. 
g. Cover the slides using Vectorshield mounting medium (H-1000), ready for further 
determination by fluorescence microscopy.  
 
For DAB staining: 
 Before block with blocking buffer (step c above), the slides need to be blocked 
with Avidin/Biotin (Vector laboratories, Inc. Burlingame, LA) for 15 min. And the slides 
are further blocked with blocking buffer, and then incubated with primary antibody for 
overnight. In the next day, the slides are incubated with proper biotinylated secondary 
antibody for 1 hr at 37 
0
C. After that, the slides are incubated with ABC (Vector 
laboratories, Inc. Burlingame, LA) solution for 30 min at 37 
0
C. Then the slides are 
washed with PBS and added with DAB solution containing DAB and hydrogen peroxide, 
and stopped the reaction by rinsing in water.  
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Chapter 5  
Results for Aim1: Determine Syk kinase expression and activity in response to UV 
exposure, in vitro and in vivo 
 
5.1. In vitro: Determine the effect of UV exposure on Syk mRNA in human dermal 
fibroblasts (HDFs) and keratinocytes (HDKs). 
 
5.1.1. UVB dosage determination 
In order to determine the proper UVR dosage for the in vitro cellular 
experiments, mouse NIH3T3 fibroblasts were exposed to different dosages of UVR, as 
indicated in Fig.5.1. Cell viability was evaluated 24 hours after UVR treatment using the 
trypan blue assay. The data indicated that cell viability was significantly decreased when 
UVR dosage was increased from 50 mJ/cm
2
 to 75 mJ/cm
2
. Statistical analysis showed 
that the change of cell viability was significant at a level p<0.001. Based on these data, a 
dosage of 60 mJ/cm
2
 for the UVB radiation was selected for future studies.  
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Figure 5.1. Effect of UVR on fibroblast viability. Cell viability was evaluated 24 hours after UV 
treatment using trypan blue assay (average of 1000 cells counting). Cell viability is presented as 
an N-fold increase in the number of dead cells from UV exposed sample over the number of dead 
cells from the unexposed to UV sample (control).   
 
5.1.2. UVB exposure increases Syk expression in HDFs and HDKs. 
Syk expression in response to UV exposure was investigated in HDFs and HDKs, 
using reverse transcription-polymerase chain reaction (RT-PCR), because the level of 
Syk expression in normal HDFs or HDKs is very low. HDFs or HDKs were exposed to 
UVB (60 mJ/cm
2
) once a day for either three or six days. The RT-PCR results 
demonstrated that UVB enhanced Syk expression in HDFs (Fig.5.2a) and HDKs 
(Fig.5.2b). 
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Figure 5.2a. UV increases Syk mRNA in human dermal fibroblasts. Lane 1 (THP-1), lane 2 (no 
UV exposure), lane 3 (3 times UV exposure), lane 4 (6 times UV exposure). UVB dosage for 
each exposure: 60 mJ/cm
2. Syk cDNA fragment (upper panel) and β-actin cDNA fragment (lower 
panel) were amplified by RT-PCR. 
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Figure 5.2b. UV increases Syk mRNA in human dermal keratinocytes. Lane 1 (THP-1), lane 2 (3 
times UV exposure), lane 3 (6 times UV exposure), lane 4 (no UV exposure). UVB dosage for 
each exposure: 60 mJ/cm
2. Syk cDNA fragment (upper panel) and β-actin cDNA fragment (lower 
panel) were amplified by RT-PCR. 
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5.2. Quantify Syk activation after UV exposure in human dermal fibroblasts. 
The effect of UVR on the dynamics of Syk activation was evaluated by 
transiently transfecting Syk cDNA into HDFs, due to the low inherent expression of Syk 
in normal HDFs. After UV exposure, cells were harvested at the indicated time points 
(Fig.5.3). Cell lysates were immunoprecipitated with anti-Syk antibody and blotted with 
anti-phosphotyrosine antibody. The results indicate higher Syk tyrosine phosphorylation 
(pTyr-Syk) in cells exposed to UV vs. unexposed cells, suggesting enhanced Syk 
activation upon UV exposure (Fig.5.3a). Syk tyrosine phosphorylation exhibited a 
maximum 25 min after UV exposure and its activation lasted for at least 45 min (Figs 
5.3a and 5.3b). Statistical analysis showed that, compared to control (without UV 
exposure), the enhancement of pTyr-Syk signal by UV (from 5 min to 45 min after UV 
exposure) is significant at a level p<0.01. 
 
52 
 
 
Figure 5.3. UV exposure enhances Syk tyrosine phosphorylation. (a) HDFs were transiently 
transfected with Syk cDNA, and 48 hours after transfection exposed to UVB  (60 mJ/cm
2
). Cells 
were lysed at 5, 10, 25 and 45 min, post UV exposure. Cell lysates were immunoprecipitated with 
anti-Syk antibody, blotted with anti-tyrosine phosphorylation antibody and the membrane was 
stripped and reblotted with an anti-Syk antibody. (b) Activation curve of Syk in HDFs after UV 
exposure. Western blot results were quantitated by image-density analysis, and phospho-Syk 
bands were normalized by Syk protein expression. The pixel/density of scanned western blot was 
obtained by Adobe Photoshop 7.0.1. 
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5.3. In Vivo: Compare Syk expression in the skin of hairless mice with vs. without UV 
exposure. (Please see the results in Chapter 6) 
 
5.4. Compare Syk expression in human skin samples: normal vs. photodamaged skin. 
5.4.1. Syk expression in normal vs. UV damaged human skin samples. 
After we obtained the results in cells and animal model (SKH1), we next would 
like to test those findings in human UV damaged skin.  In Figure 5.4 (upper panel), Syk 
expression was compared between normal and UV damaged biopsy samples of human 
skin (paraffin blocks) by immunohistochemistry. Cell nucleus was detected by Dapi-
staining (blue).  And Syk protein is detected by anti-Syk antibody plus goat anti-mouse 
florescence labeled 2
nd
 antibody (549) (red). The result indicated that more syk 
expression can be found in UV damaged skin vs. normal skin. This also confirmed that 
UV exposure enhances syk expression not only in cell line, mouse skin but also in human 
skin.  In the lower panel (Fig.5.4): the statistic analysis result for Syk expression in 
human skin samples by Matlab (detail shown in Appendices B). We used dapi-staining as 
a control which states for the cell number, and compare the ratio of syk to dapi density. 
The result suggests that there is a significant difference (at level p<0.01) between normal 
vs. UV exposed group on Syk expression despite the small number of samples evaluated.  
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Figure 5.4. UV exposure enhances Syk expression in human skin biopsies. Higher expression of 
Syk in UV exposed human skin is statistically significant at a level of p<0.01. 
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5.4.2. Location of Syk and MMP-1 protein expression in human skin samples, exposed to 
UV radiation. 
Our in vitro data have demonstrated that Syk enhances MMP-1 expression in 
human dermal fibroblasts exposed to UV. Our immunohistochemistry results (Fig.5.5) 
also suggest that elevated expression of Syk kinase can be detected in UV exposed vs. 
unexposed human skin samples. We have now used two different fluorescently labeled 
antibodies for Syk kinase (green) and MMP-1(red) and observed them in an 
immunohistochemistry assay. Our data indicate that Syk mainly expresses in the 
cytoplasm, while MMP-1 mainly expresses in the cell membrane (Fig.5.5). In most, 
MMP-1 (red) co-localizes with Syk (green), while only Syk (green) can be seen in some 
of the cells. No MMP-1 is visible before Syk expression. This may suggest that Syk 
expression precedes MMP-1 expression, which confirms our results from animal 
experiments.  
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MMP-1
(Red)
Syk
(Green)
 
 
Figure 5.5. Location of Syk and MMP-1 protein expression in cells of human skin sample 
exposed to UV. MMP-1 was recognized by anti-MMP-1 antibody plus Alexa Fluor 594 (Red) 
labeled 2
nd
 antibody; Syk was detected by anti-Syk antibody plus Alexa Fluor 488 (Green) 2
nd
 
antibody. 
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5.4.3. Syk expression in human dermal keratinocytes of UV damaged human skin. 
In Fig.5.2b, our RT-PCR result has detected Syk expression in human dermal 
keratinocytes (CRL-2309) with UV exposure. Not like human dermal fibroblasts, a good 
human dermal keratinocytes is not available. CRL-2309 (ATCC) is a human 
papillomavirus 16 (HPV-16) E6/E7 transformed skin keratinocytes. In order to confirm 
the finding in Fig.5.2b, we used two different stainings to label antibodies: Alexa Fluor 
488 for Syk kinase (green) and DAB for filaggrin antibody and observed them in an 
immunohistochemistry assay. Filaggrin is a known specific cell marker for human 
keratinocytes, which can allow us to localize the keratinocytes in human skin biopsy 
samples. Our immunohitochemistry results clearly showed Syk expression in the 
keratinocytes from UV damaged human skin samples (Fig.5.6).  
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Figure 5.6. Syk expression in UV damaged human skin samples. Human dermal keratinocytes 
was recognized by filaggrin antibody with DAB staining (brown). Syk is recognized by anti-Syk 
antibody with AlexFluor 488 staining (green). 
 
Our data has demonstrated that UV exposure enhances Syk expression and 
activity both in HDFs/HDKs and in human skin biopsies.  And it has been well known 
MMP-1 is a hallmark for UV induced damage. We next would like to further investigate 
the effect of Syk on the known Markers of UV induced damage such as MMP-1 in 
human and MMP-13 in mouse.  
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Chapter 6 
The results for Aim2: Evaluate the effect of Syk kinase on known markers of UV 
damage, in vitro and in vivo 
 
6.1. In Vitro: Evaluate the effect of Syk on key photo-damage molecules such as MMP-1. 
6.1.1. Over-expression of Syk enhances MMP-1 expression in HDFs. 
Syk cDNA was transiently transfected into HDFs. 48 hours after transfection, 
cells were exposed to UVB (60 mJ/cm
2
).  Supernatants from the cell cultures were 
harvested for western blot assay 24 hours after UV exposure. An increased amount of 
MMP-1 was found in Syk transfected cells by western blot analysis (anti-human MMP-1, 
Fig.6.1a).  Protein loading for each sample was based on OD280 measurement. 
Overexpression of Syk in HDFs transfected with Syk cDNA is shown in Fig.6.1b.  
 
Figure 6.1. Overexpression of Syk enhances MMP-1 expression in human dermal fibroblasts 
(HDFs). (a) HDFs were transfected with either Syk cDNA (lanes 2 and 3) or vector (lanes 1 and 
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4) before UVB exposure (60 mJ/cm
2
). Syk enhances MMP-1 expression upon exposure to UVB 
(lane 2 vs. lane 1). Lanes 3 and 4 are the negative controls. (b) Overexpression of Syk in HDFs 
transfected with Syk cDNA as shown by immunoblotting with anti-Syk antibody (upper panel). 
The same membrane was reblotted with anti-β-actin antibody (lower panel). 
 
6.1.2. Syk siRNA decreases MMP-1 expression in human dermal fibroblasts.  
To confirm the results shown in Fig.6.1, either control siRNA or Syk siRNA was 
transfected into HDFs 24 hours after Syk cDNA transfection. 24 hours after transfection 
of siRNA cells were exposed to UVB (60mJ/cm
2
), and after another 24 hours cell culture 
media were harvested for MMP-1 expression assay while cell lysates were used for Syk 
expression determination by western blot (Fig.6.2). Our results indicate that in contrast to 
control siRNA (lanes 4-6) and control medium (lanes 7-9), Syk siRNA (lanes 1-3) 
significantly inhibited MMP-1 expression (lower panel) by modulating Syk expression 
(upper panel). The middle panel shows results of the loading control by reblotting with 
anti-β-actin antibody.  
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Figure 6.2. Syk siRNA inhibits MMP-1 expression in human dermal fibroblasts (HDFs). HDFs 
were transfected with Syk cDNA 24 hrs before siRNA transfection. Lanes 1-3: HDFs transfected 
with Syk siRNA, Lanes 4-6: HDFs transfected with control siRNA, Lanes 7-9: HDFs with 
medium. HDFs lysates were immunoblotted with anti-Syk antibody (upper panel). The same 
membrane was reblotted with anti-β-actin antibody (middle panel).  Culture medium from each 
sample was immunoblotted with anti-MMP-1 antibody (lower panel).  
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6.2. Study the effect of Syk on the activation of its downstream molecules (MAPKs) in 
human dermal fibroblasts with UV exposure. 
Previous studies [207] have clearly demonstrated that MAPKs play an important 
role in UV induced signaling. We hypothesized that Syk affected MMP-1 expression by 
modulating the activation of MAPKs. HDFs were transiently transfected with Syk cDNA, 
and after UV exposure, cell lysates were blotted with anti-phospho-JNK, anti-phospho-
p38, and anti-phospho-Erk1/2 antibodies, respectively. The results demonstrated that only 
JNK phosphorylation was dramatically enhanced in cells transfected with Syk vs. 
controls (lane 3 vs. lane 1 and lane 4 vs. lane 2 in Fig.6.3a). Moreover, based on the result 
of reblotting with anti-JNK, the enhanced phospho-JNK was phospho-JNK1. The data 
also confirmed that UV exposure enhanced JNK activation (lane 2 vs. lane 1 and lane 4 
vs. lane 3 in upper panel of Fig.6.3a). However, in the anti-phospho-p38 blot, no signal 
change was observed in cells transfected with Syk vs. controls while, as anticipated, UV 
exposure increased p38 phosphorylation (lane 2 vs. lane 1 and lane 4 vs. lane 3 in 
Fig.6.3b). In contrast to the anti-phospho-JNK and anti-phospho-p38 blots, we did not 
find any changes of Erk1/2 signal in the presence or absence of UV exposure or in the 
presence of elevated Syk levels (Fig.6.3c). The combined results from Figs 6.3a, 6.3b, 
and 6.3c, confirmed that both JNK and p38 MAPKs, but not Erk1/2, play a role in UV 
induced signaling in HDFs, and demonstrate that only JNK1 is related with Syk 
activation. These data suggest that Syk might affect MMP-1 expression by modulating 
JNK1 activity, and thus play an important role in UV induced skin photo-damage. 
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Figure 6.3. Effect of Syk on MAPK activity in human dermal fibroblasts upon UV exposure. (a) 
JNK activation is enhanced by UV exposure and Syk kinase. HDFs were transiently transfected 
with Syk (lanes 3 and 4) or vector control (lanes 1 and 2). 48 hrs after transfection cells were 
exposed to UVB (60 mJ/cm
2
- Lanes 2 and 4). Cell lysates were blotted with anti-phospho-JNK 
antibody (upper panel), then the membrane was stripped and reblotted with anti-JNK antibody 
(middle panel), and with anti--actin antibody (lower panel). (b) p38 MAPK activation is 
enhanced by UV exposure but not by Syk kinase transfection. Cell treatment is identical to Figure 
6.3a. (c) Erk1/2 activation is independent of UV exposure. Cell treatment remained the same as in 
Figs 6.3a and 6.3b. 
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6.3. In Vivo: Determine effect of UV exposure on Syk and MMP-13 expression in the 
skin of hairless mice. 
To confirm our findings in vivo, hairless mice were exposed to UVR for either 5 
or 10 weeks as indicated in Table 4.1. In order to implement for the in vivo study a 
system more representative of human exposure to UV irradiation, a solar simulator with a 
spectrum consisting of 97 % of UVA and 3 % of UVB was employed for the animal 
studies. Syk and MMP-13 expression were measured in skin harvested from the mice 
after UV exposure. Our results showed that Syk expression was dramatically enhanced in 
skin samples after either 5 or 10 weeks of UV exposure (Panel A of Figs 6.4a and 6.5a). 
Statistical analysis showed that the enhancement of Syk expression in skin samples upon 
UV exposure (5 or 10 weeks) is significant at a level p<0.002. However, MMP-13 
expression was found to clearly increase only in the samples exposed to UV for 10 weeks 
(Panel B of Fig.6.5a), and showed no significant increase in skin samples exposed to UV 
for 5 weeks (Panel B of Fig. 6.4a).  In panel C of Figs 6.4a and 6.5a, the same 
membranes were reblotted with anti--actin to determine the loading of protein. These 
results demonstrate that Syk is altered earlier than MMP-13 in the skin of hairless mice 
after UV exposure, and suggest that Syk might be an earlier biomarker for UV induced 
photo-damage. Figure 6.6 showed positive correlation between Syk and MMP-13 
expression and demonstrated dose dependence of Syk and MMP-13; higher Syk levels 
result in higher MMP-13 expression in the skin of hairless mice exposed to UV. 
Therefore, Syk enhances expression of collagenase: MMP-1 in HDFs in vitro and MMP-
13 in the skin of hairless mice in vivo.  
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Figure 6.4. Effect of UV exposure (5 weeks) on Syk and MMP-13 expression in the skin of 
SKH1 hairless mice. (a): Lanes 1-7: Samples (7 mice) with UV exposure. Lanes 8-9: Samples (2 
mice) without UV exposure. (b): Image density analysis of results in upper panel.  
b 
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Figure 6.5. 10 week UV exposure enhances Syk and MMP-13 expression in hairless mouse skin. 
(a) Lanes 1-5: Samples (5 mice) after UV exposure. Lanes 6,7: Samples (2 mice) without UV 
exposure. (b) Image density analysis of results in upper panel.  
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Figure 6.6. Relationship between Syk and MMP-13 expression in the skin of hairless mice. 
Western blot results in Figs. 6.4 and 6.5 were quantified by image-density analysis. Expression 
levels of Syk and MMP-13 were normalized by the actin expression level for each sample, and 
are presented in a scatter plot. The smaller slope for the samples exposed to UV for 5 weeks 
compared to the samples exposed to UV for 10 weeks suggests that Syk expression is preceding 
MMP-13. 
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Chapter 7 
 The results for Aim 3: Evaluate the effect of Syk kinase inhibitors on known 
markers of UV damage 
 
7.1. In Vitro: Evaluate the effect of a Syk kinase inhibitor on key photo-damage 
mediator-MMP-1 in human dermal fibroblasts and keratinocytes. 
7.1.1. MMP-1 expression is decreased by Syk inhibitor in HDFs. 
HDFs were pre-treated (before UV exposure) with different kinase inhibitors, as 
indicated in Fig.7.1a. We found that MMP-1 expression was significantly inhibited by the 
Syk inhibitor piceatannol (25g/ml) (lane 3 in Fig.7.1a) [208]. The dose-response of 
piceatannol inhibition was assessed in HDFs exposed to UVB (60 mJ/cm
2
) (Fig.7.1b). 
Our western blot data indicated that MMP-1 expression was dramatically (63%) inhibited 
by piceatannol at a concentration of 25 g/ml. Statistical analysis showed that this 
inhibition of MMP-1 expression by piceatannol (25 g/ml) compared to control (without 
piceatannol) is significant at a level p<0.01, while only 20% inhibition was found at a 10 
g/ml piceatannol. There was no inhibition of MMP-1 expression by lower 
concentrations of piceatannol such as 1 g/ml and 5 g/ml, as demonstrated by the 
density analysis in Fig.7.1c.  
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Figure 7.1. MMP-1 expression is decreased by piceatannol (Syk inhibitor) in human dermal 
fibroblasts (HDFs). (a) Syk inhibitor piceatannol inhibits the expression of MMP-1 (lane 3). 
HDFs were pretreated with kinase inhibitors before UV exposure, lane 1 (control), lane 2 (Src 
family tyrosine kinase (SRTK) inhibitor-PP2), lane 3 (Syk inhibitor-Piceatannol), lane 4 (PI3 
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kinase inhibitor-Wortmannin), and lane 5 (PKC4 inhibitor-Bisindolylmaleimide l). 24 hours after 
UV exposure, cell culture media were collected for western blot assay. Loading amount for each 
sample is based on the absorbance at O.D280. (b) Dose-dependent test for piceatannol in HDFs. 
HDFs were pre-incubated with different concentrations of piceatannol: 1 g/ml, 5 g/ml, 10 
g/ml, and 25 g/ml respectively. 24 hours after UVB (60 mJ/cm2) exposure, culture media were 
collected for MMP-1 assays. (c) Western blot results in Fig.7.1b were quantitated by image-
density analysis. The pixel/density of scanned western blot was obtained by Adobe Photoshop 
7.0.1. 
 
7.1.2. Syk inhibitor reduces MMP-1 expression in human dermal keratinocytes (HDKs). 
Human dermal keratinocytes (CRL-2309) were pretreated with different 
concentration of piceatannol as indicated in Fig.7.2, the cells were further exposed to 
UVB at 60 mJ/cm
2
. 24 hrs after UV exposure, cell culture media were collected for 
MMP-1 expression assay by western blot. Compared to the control without piceatannol, 
MMP-1 expression was dramatically inhibited by piceatannol at a concentration of 25 
g/ml. Statistical analysis showed that, compared to control (without piceatannol), this 
inhibition of MMP-1 expression by piceatannol (25 g/ml) is significant at a level 
p<0.01. However there was no inhibition of MMP-1 expression by lower concentration 
of piceatannol such as 1 g/ml (Fig.7.2).  
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Figure 7.2. Effect of Syk inhibitor on MMP-1 expression in HDKs.  (a) HDKs were pretreated 
with different concentration of piceatannol (1, 5, 10, and 25 μg/ml). Cells were further exposed to 
UVB at 60 mJ/cm
2
. 24 hrs after UV exposure, cell culture media were harvested and 
immunoblotted with anti-MMP-1 antibody. Sample loading was based on the absorbance at 
O.D280. (b) Western blot results in Fig.7.2a were quantitated by image-density analysis. The 
pixel/density of scanned western blot was obtained by Adobe Photoshop 7.0.1. 
 
 
a 
b 
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7.1.3. Compare MMP-1 expression in HDFs and HDKs with UV exposure. 
HDFs and HDKs were taken the same treatment such as UVB exposure and 
piceatannol incubation. Cell culture media were immunoblotted with anti-MMP-1 
antibody. In order to ensure the developing condition exact same, the western blot results 
of MMP-1 expression in HDFs and HDKs were developed on the same film.  The results 
show that much stronger MMP-1 signal can be found in HDFs than in HDKs even much 
less (10 times less) HDFs than HDKs used in our assay (Fig.7.3). It demonstrates that UV 
induced MMP-1 expression is much higher in each HDFs than in each HDKs.  
 
 
Figure 7.3. Compare UV induced MMP-1 expression in HDFs and HDKs. 
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7.2. In Vivo: Study the effect of a Syk inhibitor (piceatannol) on MMP-13 expression in 
the skin of SKH1 hairless mice with 10 week UV exposure.  
In order to further confirm the findings in Figs. 7.1 and 7.2 in vivo and explore the 
potential application of Syk inhibitor for UV induced skin damage, the skin of SKH1 
mice were pretreated with Syk inhibitor (piceatannol) before every scheduled UV 
exposure. After 10 weeks treatment, the mice were sacrificed and skins were collected for 
MMP-13 expression assay by western blot. The results indicate that MMP-13 expression 
is inhibited in the piceatannol treated groups vs. no piceatannol treated group. Statistical 
analysis also showed that, compared to control (without piceatannol), this inhibition of 
MMP-13 expression by piceatannol is significant at a level p<0.001 (Fig.7.4). It suggests 
that not only Syk expression (Figs. 6.1, 6.2, 6.4 and 6.5) but its activity is important for 
the effect of Syk on UV induced skin damage (Fig. 7.4).   
 
 
 
 
a 
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Figure 7.4. Effect of piceatannol on MMP-13 expression in the skin of SKH1 hairless mice. (a) 
Lane 1-4 samples (4 mice): with UV exposure (10 weeks). 5-8 samples (4 mice): pretreated with 
piceatannol before UV exposure (10 weeks). The detail has been shown in method part. Upper 
panel: blotted with anti-MMP-13 antibody; lower panel: blotted with anti-β-actin antibody 
(protein loading control). (b) Western blot results in Fig.7.4a were normalized by β-actin 
expression and quantitated by image-density analysis. The pixel/density of scanned western blot 
was obtained by adobe photoshop 7.0.1. 
 
 
b 
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Chapter 8: Conclusion and Discussion  
 
Although recent studies indicate that Syk can be expressed by many non-
hematopoietic cells [185-187], in this study we report for the first time an enhanced Syk 
expression in human dermal fibroblasts (HDFs) and Keratinocytes (HDKs) in response to 
UV exposure (Fig.5.2 - RT-PCR results). Our data also demonstrate that overexpression 
of Syk enhances MMP-1 expression in HDFs in response to UV exposure (Fig.6.1), while 
MMP-1 expression is inhibited in a dose dependent fashion by a Syk inhibitor in both 
HDFs and HDKs (Figs. 7.1 and 7.2). Furthermore, the effect of Syk on MMP-1 
expression was proven by transfection of Syk siRNA in HDFs, and that results in 
inhibition of MMP-1 expression (Fig.6.2). These data suggest that Syk could play an 
important role in UV induced skin damage by modulating MMP-1 expression.Lately Syk 
has become very important target in the study of many diseases.  Recently, several groups 
have made great inroads on the relationship between Syk and immune diseases. An oral 
Syk inhibitor (R788) reduced disease activity in patients with rheumatoid arthritis in a 
phase 2 clinical trial [209]. Syk inhibitor R788 also has been shown to protect mice 
against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung 
injury [210]. In lupus-prone mice, this same Syk inhibitor R788 was found to suppress 
the development of lupus skin and kidney disease [211].  
In elucidating the role of Syk activation in skin UV damage, our data indicate that 
tyrosine phosphorylation of Syk increases within 5 minutes after UV exposure and 
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reaches a maximum 25 minutes after UV exposure (Fig.5.3). Data from previous studies 
[29,35] demonstrated that stimulation of MMP expression occurred through upregulation 
of transcription factors AP-1 and NF-B. These changes in transcription factors could be 
detected within a few minutes and reached a maximum 60 minutes after UVB exposure. 
Elevated MMP levels and activities were detectable approximately 16 hrs after UVB 
exposure, and reached their highest level after 24 hrs [29,35]. In contrast to MMP 
expression, Syk activation was altered much faster upon UV exposure. This may be 
related to its position upstream of MMP-1 in the signaling cascade of response to UV. 
The data in our cell experiments indicate that UV exposure enhances both 
expression and activity of Syk kinase, and that Syk increases those key UV damage 
markers such as MMP-1 expression. Although acute and chronic UV exposures share 
many similar effects such as decreasing the number of dendritic Landerhan cells [22-24] 
and increasing MMP experession [27-32], chronic UV effect is thought as the main 
reason causing skin photodamage and some skin cancers.  It is hard to evaluate the 
chronic effect by UV in cell models because of the limitation by cell growth generation. 
In order to confirm the new findings of Syk functions in UV radiation from our cell 
models (acute effect of UV), our in vivo studies on hairless mice further demonstrate that 
UV exposure also enhances both Syk and MMP-13 expression in the skin of hairless 
mice exposed to UV for 10 weeks (Fig.6.5). Our data also indicate that Syk has a positive 
correlation with MMP-13 expression in the skin of hairless mice upon UV exposure 
(Fig.6.6). This confirms our previous in vitro findings that Syk enhances MMP-1 
expression in HDFs (Fig.6.1). In skin samples of mice exposed to UV for 5 weeks, we do 
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not observe significant alternation of MMP-13 expression, while changes in Syk 
expression can still be clearly detected (Fig. 6.4). This suggests that Syk may be an 
earlier marker to MMP-1 for UV induced skin photo-damage, and could play an 
important role in the protection and remediation of UV induced skin photo-damage 
because collagen repair is a slow and lengthy process after collagen has been degraded by 
the activated MMPs.  
In this study, we also investigated the effect of Syk on MAPKs activation in 
human dermal fibroblasts exposed to UV. Our data indicate that Syk only enhances JNK 
phosphorylation (Fig.6.3a), but not p38 (Fig.6.3b) or Erk1/2 phosphorylation (Fig.6.3c), 
although p38 is activated under the same conditions of UV exposure (Fig.6.3b). This 
suggests that Syk may enhance MMP-1 expression by modulating JNK activation, and 
may be linked to the published results where Syk inhibitor R406 suppressed JNK 
activation and MMP-3 gene expression in (TNFα)-stimulated fibroblast-like synoviocytes 
[204]. In addition, as indicated above, UV induced phospho-JNK1 has been linked with 
UV-induced tumor promotion by binding and activating c-Jun transcription factor [116]. 
Thus, it suggests that Syk may also play the role in UV induced skin tumor development.   
In contrast to the clear effect of UV on the activation of stress-activated protein kinases 
(JNK and p38), Erk1/2 MAPK activation depends on the level and type of UV exposure. 
Phosphorylation of JNK, p38 and Erk1/2 can be enhanced by a single UVB exposure of 
SKH-1 hairless mice at a dosage of 180 mJ/cm
2
 [212]. However, it has been reported that 
UVB at 450 mJ/cm
2
 and UVC at 150 mJ/cm
2
 do activate JNK and p38 but not Erk1/2 in 
human lens epithelial cells (HLE)
 
[213]. Findings by Nakamura et al, [214]
 
also agree 
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with our data where JNK and p38 phosphorylation, but not Erk1/2, are increased by 
UVB. The response of Syk to lower levels of UVB exposure is important as it may relate 
to chronic UV damage by exposure at levels at or below minimal erythema dosages. 
Finally, our data from human biopsies demonstrates that elevated Syk expression 
can be found in the UV exposed skin compared to skin unexposed to UV (Fig.5.4). 
Although the evaluated sample number is not large, the difference is statistically 
significant. More samples are being collected. The significance of these results is that it is 
possible to detect Syk from already collected biopsies by methods readily available to 
pathology labs (immunohistochemistry).  
Many tumors express high levels of MMPs and therefore MMP inhibitors have 
been the subject of many studies. However, recent clinical trial results have proven that 
broad specificity small-molecule MMPs inhibitors designed to coordinate the active site 
zinc atom, which is crucial for activity in all MMPs, are less useful than initially thought 
because they lacked efficacy and caused side-effects in phase III clinical trials [166,167]. 
One of the major problems in targeting MMPs is that this enzyme family is structurally 
highly similar, particularly in the vicinity of the active site, so it is difficult to achieve 
selective inhibition. For instance, recently several MMPs including MMP-8, MMP-3, and 
MMP-12 have been demonstrated to have antitumor effects in mouse models of cancer 
[215]. Especially, MMP-8 has been thought as a tumor suppressor gene and shown to 
protect against skin tumor development via changes in neutrophil influx following 
chemokine processing [216] and by reduction in metastasis by the alteration in cell 
adhesion to ECM components [217]. The evidence for a protective antitumorigenic role 
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of MMP-8 was also confirmed by the genetic analysis of MMP-8 mutations in human 
melanomas. Inactivating mutations of MMP-8 resulted in increased colony growth of 
melanoma cells in soft agar and tumor formation in vivo compared to melanomas-
expressing wild type MMP-8 [216]. 
This is one of the reasons why MMP inhibitors when tested in human cancer 
therapy failed to slow, and they even sped up, tumor growth in some cases due to 
inhibition of tumor suppressors like MMP-8. Many drug companies now regard the 
whole MMP family as anti-targets not worth pursuing for long term treatment of chronic 
disease.  Instead of focusing on substrate-binding sites located in the catalytic domain, 
companies now are developing the inhibitors against exosites of MMPs, which are 
auxiliary protein-binding motifs in noncatalytic MMP domains. Those inhibitors show 
enhanced selectivity for specific MMPs and MMP activities. 
In conclusion, UV exposure enhances expression and activation of Syk kinase in 
human dermal fibroblasts and keratinocytes. Syk increases MMP-1 expression in HDFs 
and HDKs, and our results indicate that Syk may affect MMP-1 expression by 
modulating JNK activity in human dermal fibroblasts with UV exposure. Experiments 
with hairless mice further indicate that UV exposure enhances both Syk and MMP-13 
expressions in the skin of SKH1 mice, and there is a positive correlation between Syk and 
MMP-13. And our animal experiments also demonstrate that both Syk expression and its 
activity are required for Syk playing an important role in UV induced skin damages. 
These new findings suggest that Syk may become a useful therapeutic target and an 
earlier biomarker to MMP-1 for UV induced skin photo-damage (Fig.8.1). 
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Figure 8.1. The role of Syk in UV mediated skin damage. 
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Chapter 9: Future Plan 
 
It has been indicated that the skin is no longer considered as a just simple passive 
barrier, but rather a part of immune system. For instance, neutrophils are known for their 
destructive capacity and are considered to be responsible for the ECM damage observed 
in several conditions [218]. Furthermore, neutrophils have been reported to infiltrate the 
skin following exposure to erythemogenic doses of UVB, solar simulating radiation 
(SSR), and natural sunlight [219,220]. Neutrophils also have been shown to express 
MMP-8, MMP-9, and MMP-12 [221], and MMP-1 also co-localized with neutrophil 
elastase and stay with enzymatically active form in infiltrating cells following solar 
simulating radiation exposure [220,222]. Although skin immune system hasn‟t been 
obtained enough attention for a long time, more and more evidence suggests that they 
could be one of the major players in UV induced photodamages. Therefore, it will be 
very important to evaluate the effect of skin immune system on UV induced skin 
damages. 
In order to explore unknown molecules in UV-Syk-JNK1-MMP pathway, the role 
of Vav and Rac1, which have been shown to relate with the effect of Syk on JNK 
activation [199], will be determined by either Vav siRNA or Rac1 siRNA. And the 
activation of Vav and Rac1 will be compared in human fibroblasts and keratinocytes with 
vs. without Syk overexpression after UV exposure. The association between Syk and 
Vav/Rac1 will be examined through coimmunoprecipitation assay. 
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  We have identified elevated Syk expression in biopsy samples from the skin of 
patients exposed to UV compared to unexposed skin (Fig.5.4). The difference is 
statistically significant despite the small number of samples evaluated.  Our 
immunohistochemistry data also show that more Syk expresses in squamous cell 
carcinoma (SCC) and basal cell carcinoma (BCC) samples vs. normal control (Fig.A1).  
In order to obtain the statistically reliable analysis result, we would like to continue 
testing samples obtained from biopsies of various skin cancers to establish a sample 
population. And the normal control (UV unexposed) samples will be collected from the 
same donor ensuring a tighter baseline, where each patient acts as its own control, so that 
it will make the results more accurate. Meantime, we will also try to analyze Syk 
expression in those samples by more accurate method -quantitative PCR. In order to 
further understand the function of Syk in skin cancer progression, skin carcinoma animal 
models will be built in SKH1 hairless mice exposed to UV. The role of Syk inhibitors 
(piceatannol or R788) in preventing skin carcinogensis will be determined in those 
animal models. Compared with chemical inhibitors, Syk siRNA is thought as a more 
specific and less side effect inhibitor for syk kinase. Therefore, Syk siRNA also will be 
evaluated as potentials of preventing UV damage and progression to skin carcinogenesis 
in animal experiments.  
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Appendices A 
 
Compare Syk expression in normal skin samples (UV unexposed) vs. SCC/BCC. 
It is known that UV radiation is the major reason to cause skin cancer. In order to 
test Syk as a potential marker for UV induced skin cancers, we compared Syk expression 
in normal skin samples vs. SCC or BCC samples from the same patients. Cell nuclear 
was detected by Dapi-staining (blue).  And Syk protein is detected by anti-Syk antibody 
plus goat anti-mouse fluorescence labeled 2
nd
 antibody (549) (red). The result indicated 
that more syk expression could be detected in BCC or SCC vs. normal skin (Fig.A1). The 
result analysis for Syk expression in human skin samples was performed by Matlab 
(detail shown in Appendices B). We used dapi-staining as a control which states for the 
cell number. And compare the ratio of syk to dapi density. In order to obtain the 
statistically reliable analysis result, we would like to continue testing samples obtained 
from biopsies of various skin cancers in order to establish a sample population. 
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Figure A1. Syk expression in normal skin samples vs BCC/SCC sample. Cell nucleus is 
recognized by Dapi (blue). Syk is recognized by anti-Syk antibody plus goat anti-mouse 
florescence labeled 2
nd
 antibody (549) (red).  
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Appendices B 
 
 
Figure B1. Picture of Fluorescence microscope 
 
Software for image data analysis by Matlab: 
close all  % Close any open windows 
filepath='C:\imageanalysis\dapi\'; % Enter the path where your DAPI 
images are located 
files = dir(fullfile(filepath,'n*.psd')); % Select all 'PSD' image 
files with filename that starts with 'n' 
filenames = char(files.name); % Read all the matching filenames within 
your folder to an array 
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for i = 1:size(filenames,1) % Loop through each unique filename 
    filename = filenames(i ,:); % Select the ith filename from the 
filename array 
    [Y,Ymap]= imread([filepath filename]); % read the selected image 
file into Matlab 
    Y_b=Y(:,:,3); % Select the third channel of the image file (Blue 
channel if the file is RGB) 
    imshow(Y_b),% Display the blue channel of the image on the screen 
    impixelinfo; % Display the intensity value of the pixel under the 
cursor 
    figure % Open a new figure 
    thresh_raw=100; % Select a threshold intensity level for filtering 
background noise (0-255) 
    thresh=thresh_raw/255; % Normalize the threshold (0-1) 
    BW = im2bw(Y_b,thresh); %Create binary image in which 
pixel_intensities > threshold = 1 and pixel_intensities < 
threshold = 0 
    imshow(BW); % Display the binary image on the screen 
    impixelinfo; % Display the intensity value of the pixel under the 
cursor (0 or 1) 
    pix_int=sum(sum(BW)) % Sum of all '1' pixels in the binary image 
(i.e. number of pixels that are NOT background) 
    fid1 = fopen([filepath 'dapi_pixel_int_output.txt'],'a'); % Open a 
text output file 
   
fprintf(fid1,'%g\t%g\t%s\t%s\t\n',thresh_raw,pix_int,filepath,fil
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ename); % Write the threshold, pixel_intensity, and file 
path/name to the text output file 
    fclose(fid1); % close the text output file 
end % end the loop 
  
filepath='C:\imageanalysis\syk\';% Enter the path where your SYK images 
are located 
files = dir(fullfile(filepath,'*.psd')); % Select all 'PSD' image files 
filenames = char(files.name); % Read all the matching filenames within 
your folder to an array 
for i = 1:size(filenames,1)% Loop through each unique filename 
    filename = filenames(i ,:); % Select the ith filename from the 
filename array 
    [Y,Ymap]= imread([filepath filename]); % read the selected image 
file into Matlab 
    Y_r=Y(:,:,1); % Select the first channel of the image file (Red 
channel if the file is RGB) 
    imshow(Y_r),% Display the red channel of the image on the screen 
    impixelinfo; % Display the intensity value of the pixel under the 
cursor 
    figure % Open a new figure 
    thresh_raw=100; % Select a threshold intensity level for filtering 
background noise (0-255) 
    thresh=thresh_raw/255; % Normalize the threshold (0-1) 
    BW = im2bw(Y_r,thresh); %Create binary image in which 
pixel_intensities > threshold = 1 and pixel_intensities < 
threshold = 0 
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    imshow(BW); % Display the binary image on the screen 
    impixelinfo; % Display the intensity value of the pixel under the 
cursor (0 or 1) 
    thresh_pix_int=sum(sum(BW)) % Sum of all '1' pixels in the binary 
image (i.e. number of pixels that are NOT background) 
    fid1 = fopen([filepath 'syk_pixel_int_output.txt'],'a');% Open a 
text output file 
    
fprintf(fid1,'%g\t%g\t%s\t%s\t\n',thresh_pix_int,thresh_raw,filep
ath,filename);% Write the threshold, pixel_intensity, and file 
path/name to the text output file 
    fclose(fid1); % close the text output file 
end 
 
To determine the threshold value for our Matlab code, we manually inspected 
several images using Adobe Photoshop, and found that regions of interest (i.e. regions of 
fluorescence) had intensity values greater than 100, and usually had intensity values 
greater than 150.  The background regions had intensity values less than 100, and usually 
the background intensity values were less than 50.  Therefore, we chose 100 as a 
threshold to be sure that any background light would not be counted by the code as 
fluorescence.  
The first section of code opens all the DAPI images and analyzes the blue channel 
(channel 3 of RGB).  The second section of code opens all the SYK images and analyzes 
the red channel (channel 1 of RGB). The analysis is the same except for the names of the 
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files that are opened and the RGB channel that is analyzed.  The Matlab code counts the 
number of pixels in each image that have intensity greater than some threshold (we chose 
threshold=100).  As each image is analyzed, one line of text containing the image name 
and the number of pixels with intensity greater than 100 is sent to an output file.   
We opened the output file using Excel.  In Excel, we calculated the ratio of SYK 
pixels to DAPI pixels -- this is a normalization procedure to account for images that 
contain different numbers of cells.  Then we calculated the average SYK/DAPI ratio for 
specimens that were exposed to UV radiation and the average SYK/DAPI ratio for 
control specimens.  We compared the exposed vs. control data using a two-tailed 
heteroscedastic (assumes unequal variance in each group) t-test.  There was a significant 
difference (p<0.01) between the exposed and control groups. 
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